Настройки

Укажите год
-

Небесная энциклопедия

Космические корабли и станции, автоматические КА и методы их проектирования, бортовые комплексы управления, системы и средства жизнеобеспечения, особенности технологии производства ракетно-космических систем

Подробнее
-

Мониторинг СМИ

Мониторинг СМИ и социальных сетей. Сканирование интернета, новостных сайтов, специализированных контентных площадок на базе мессенджеров. Гибкие настройки фильтров и первоначальных источников.

Подробнее

Форма поиска

Поддерживает ввод нескольких поисковых фраз (по одной на строку). При поиске обеспечивает поддержку морфологии русского и английского языка
Ведите корректный номера.
Ведите корректный номера.
Ведите корректный номера.
Ведите корректный номера.
Укажите год
Укажите год
Применить Всего найдено 266. Отображено 100.
08-01-2015 дата публикации

Methods and Compositions for Treatment and Prevention of Major Depressive Disorder

Номер: US20150010534A1
Автор: Pomara Nunzio
Принадлежит:

The present invention relates to methods of diagnosing, prognosing or treating diseases or disorders in which elevated levels of Abeta protein, including abetaare prevalent. In particular, the present invention relates to methods of diagnosing, prognosing or treating a major or minor depressive episode/disorder attributed to elevated levels of Abeta protein, including abeta, found particularly in body fluids including whole blood, blood cells, serum, plasma, urine and CSF. The invention also relates to the treatment of these disorders by administering an agent that either prevents production of Abeta, prevents aggregation of Abeta fibrils, or that increases the degradation or clearance of Abeta. In addition, the invention provides a method of treating or preventing a major or minor depressive disorder comprising administering an agent that prevents or interferes with Abeta-induced neurotoxicity. The present invention also relates to pharmaceutical compositions comprising such agents and methods of screening for novel agents. 1. A method of screening , diagnosis or prognosis of a major or minor depressive episode/disorder in a subject , or for identifying a subject at risk for developing a major or minor depressive episode/disorder , or for monitoring the effect of therapy administered to a subject having a major or minor depressive episode/disorder , said method comprising:a) collecting a biological test sample from said subject;b) analyzing said test sample for the presence of amyloid beta levels; andc) comparing the level of amyloid beta in the test sample with the level of amyloid beta in one or more persons free from a major or minor depressive episode/disorder, or with a previously determined reference range for amyloid beta established from subjects free of a major or minor depressive disorder.2. (canceled)3. The method of claim 1 , wherein the elevation of amyloid beta in a subject correlates with the presence of a major or minor depressive episode/disorder.4 ...

Подробнее
Номер записи: 1
08-01-2015 дата публикации

ANTI-CD25 ANTIBODIES AND THEIR USES

Номер: US20150010538A1
Автор: AKAMATSU Yoshiko, HARDING Fiona A.
Принадлежит: AbbVie Biotherapeutics Inc.

The present disclosure relates to antibodies directed to CD25 and uses of such antibodies, for example to suppress organ transplant rejection or to treat multiple sclerosis. 1. A monoclonal anti-CD25 antibody or an anti-CD25 binding fragment of a monoclonal antibody , which:(a) binds to human CD25;(b) comprises CDRs having up to 8, up to 7, up to 6, up to 5, up to 4, up to 3 or up to 2 amino acid substitutions as compared to CDRs of SEQ ID NO:4 (CDR-H1), SEQ ID NO:6 (CDR-H2), SEQ ID NO:8 (CDR-H3), SEQ ID NO:11 (CDR-L1), SEQ ID NO:13 (CDR-L2) and SEQ ID NO:15 (CDR-L3); and{'sub': 50', '50, '(c) has an ICof up to 50% of the ICof a corresponding antibody having CDRs of SEQ ID NOs:4, 6, 8, 11, 13, and 15 in an IL2-dependent T-cell proliferation assay.'}28-. (canceled)9. An monoclonal anti-CD25 antibody or an anti-CD25 binding fragment of a monoclonal antibody , which:(a) binds to human CD25;(b) comprises heavy and light chain variable regions having up to 12, up to 11, up to 10, up to 9, up to 8, up to 7, up to 6, up to 5 or up to 4 amino acid substitutions as compared to the heavy and light variable regions of SEQ ID NO:1 and SEQ ID NO:2, respectively; and{'sub': 50', '50, '(c) has an ICof up to 50% of the ICof a corresponding antibody having the heavy and light variable regions of SEQ ID NO:1 and SEQ ID NO:2, respectively, in an IL2-dependent T-cell proliferation assay.'}1023-. (canceled)24. A monoclonal anti-CD25 antibody or an anti-CD25 binding fragment of a monoclonal antibody , which:(b) binds to human CD25;(b) comprises CDRs having up to 8, up to 7, up to 6, up to 5, up to 4, up to 3 or up to 2 amino acid substitutions as compared to CDRs of SEQ ID NO:4 (CDR-H1), SEQ ID NO:6 (CDR-H2), SEQ ID NO:8 (CDR-H3), SEQ ID NO:11 (CDR-L1), SEQ ID NO:13 (CDR-L2) and SEQ ID NO:15 (CDR-L3); and (i) heavy chains CDRs comprising at least one substitution present in any of the CDR variants H1-H354 as shown in Table 20; and/or', '(ii) light chain CDRs comprising at least one ...

Подробнее
Номер записи: 2
08-01-2015 дата публикации

HUMAN PAC1 ANTIBODIES

Номер: US20150010560A1
Автор: Hamburger Agnes Eva, XU Cen
Принадлежит:

Antibodies and antigen-binding fragments thereof that bind to human PAC1 are provided. Nucleic acids encoding the antibodies and antigen-binding fragments thereof, vectors, and cells encoding the same are also provided. The antibodies and antigen-binding fragments thereof can inhibit binding of PAC1 to PACAP, and are useful in a number of PAC1 related disorders, including the treatment and/or prevention of headache disorders, including migraine. 1. An isolated antibody or antigen-binding fragment thereof that specifically binds human PAC1 , comprising(A) a light chain CDR1 comprising (i) an amino acid sequence selected from the group consisting of the LC CDR1 sequences set forth in Table 5A, (ii) an amino acid sequence at least 90% identical to an amino acid sequence selected from the group consisting of the LC CDR1 sequences set forth in Table 5A, or (iii) an amino acid sequence at least 95% identical to an amino acid sequence selected from the group consisting of the LC CDR1 sequences set forth in Table 5A;(B) a light chain CDR2 comprising (i) an amino acid sequence selected from the group consisting of the LC CDR2 sequences set forth in Table 5A, (ii) an amino acid sequence at least 90% identical to an amino acid sequence selected from the group consisting of the LC CDR2 sequences set forth in Table 5A, or (iii) an amino acid sequence at least 95% identical to an amino acid sequence selected from the group consisting of the LC CDR2 sequences set forth in Table 5A;(C) a light chain CDR3 comprising (i) an amino acid sequence selected from the group consisting of the LC CDR3 sequences set forth in Table 5A, (ii) an amino acid sequence at least 90% identical to an amino acid sequence selected from the group consisting of the LC CDR3 sequences set forth in Table 5A, or (iii) an amino acid sequence at least 95% identical to an amino acid sequence selected from the group consisting of the LC CDR3 sequences set forth in Table 5A;(D) a heavy chain CDR1 comprising (i) an ...

Подробнее
Номер записи: 3
08-01-2015 дата публикации

Semaphorin 3C (Sema3C) Inhibitor Therapeutics, Methods, and Uses

Номер: US20150010561A1
Автор: Gleave Martin E., HAYASHI Norihiro, Ong Christopher J., Peacock James
Принадлежит:

Provided are methods, uses and pharmaceutical compositions for treatment of prostate cancer with a SEMA3C inhibitor in a biologically effective amount sufficient to cause cell death of a prostate cancer cell or to inhibit proliferation of the prostate cancer cells. The prostate cancer may be an androgen receptor (AR) positive prostate cancer and the SEMA3C inhibitor may be selected from one or more of the following: an antibody, a SEMA3C peptide, an antisense RNA, a siRNA, a shRNA or a small molecule. 164-. (canceled)65. A pharmaceutical composition comprising a therapeutically effective amount of an anti-SEMA3C antibody having SEMA3C inhibitory activity in combination with a physiologically acceptable carrier.66. The pharmaceutical composition of claim 65 , wherein the anti-SEMA3C antibody is selected from one or more of the following: a polyclonal antibody; a monoclonal antibody; an antigen binding fragment of an antibody; or a single chain antibody.67. The pharmaceutical composition of claim 65 , wherein the anti-SEMA3C antibody is a monoclonal antibody.68. The pharmaceutical composition of claim 65 , wherein the anti-SEMA3C antibody is a polyclonal antibody.69. The pharmaceutical composition of claim 65 , wherein the anti-SEMA3C antibody is an antigen binding fragment of an antibody.70. The pharmaceutical composition of claim 65 , wherein the anti-SEMA3C antibody is a single chain antibody.71. The pharmaceutical composition of claim 65 , formulated for administration with an androgen deprivation therapy.72. The pharmaceutical composition of claim 71 , wherein androgen deprivation therapy is selected from one or more of the following: a luteinizing hormone-releasing hormone (LHRH) analog; an anti-androgen compound; and an adrenal androgen inhibitor.73. The pharmaceutical composition of claim 72 , wherein the androgen deprivation therapy is a luteinizing hormone-releasing hormone (LHRH) analog.74. The pharmaceutical composition of claim 72 , wherein the androgen ...

Подробнее
Номер записи: 4
08-01-2015 дата публикации

Anti-igf antibodies

Номер: US20150010574A1
Автор: Eric Borges, Paul Adam
Принадлежит: BOEHRINGER INGELHEIM INTERNATIONAL GMBH

Antibody molecules, in particular fully human antibodies that bind to human IGF-1 and cross-react with IGF-2 such that binding of IGF-1 and IGF-2 to the IGF-1 receptor is prevented and IGF-1 receptor-mediated signaling is inhibited. The antibodies do not bind to insulin and thus do not affect the mitogenic properties of insulin that are mediated by its binding to the insulin receptors. The antibodies are useful for the treatment of hyperproliferative diseases, in particular cancer.

Подробнее
Номер записи: 5
15-01-2015 дата публикации

Methods for treating eosinophilic esophagitis by administering an il-4r inhibitor

Номер: US20150017176A1
Автор: Ana Kostic, Brendan J. Classon, Ludmila Kelly, Xia Liu
Принадлежит: Regeneron Pharmaceuticals Inc

The present invention provides methods for treating, preventing or reducing the severity of eosinophilic esophagitis. The methods of the present invention comprise administering to a subject in need thereof a therapeutic composition comprising an interleukin-4 receptor (IL-4Rα) inhibitor such as an anti-IL-4Rα antibody.

Подробнее
Номер записи: 6
29-01-2015 дата публикации

OPTIMIZED Fc VARIANTS

Номер: US20150030592A1
Автор: Gregory Lazar, John Desjarlais, Jost Vielmetter, Omid Vafa, Robert Hayes, Sher Karki, Wei Dang
Принадлежит: Xencor Inc

The present invention relates to Fc variants having decreased affinity for FcγRIIb, methods for their generation, Fc polypeptides comprising optimized Fc variants, and methods for using optimized Fc variants.

Подробнее
Номер записи: 7
29-01-2015 дата публикации

ANTI-EGFR ANTIBODY AND ANTI-C-MET/ANTI-EGFR BISPECIFIC ANTIBODIES COMPRISING THE SAME

Номер: US20150030599A1
Автор: CHEONG Kwang Ho, Cho Mi Young, HWANG Jae Woong, Koh Young Jun, LEE Jung Wook, LEE Seung Hyun, Lin Powei
Принадлежит:

An anti-EGFR scFV fragment, an anti-c-Met/anti-EGFR bispecific antibody including the same, and a method of preventing and/or treating a cancer using the same are provided. 1. A polypeptide comprising one amino acid sequence , or a combination of two or more amino acid sequences , selected from the group consisting of SEQ ID NOs: 109 to 114.2. The polypeptide according to claim 1 , wherein the polypeptide comprises:SEQ ID NO: 115, SEQ ID NO: 117,SEQ ID NO: 116, SEQ ID NO: 118, ora combination thereof.3. An anti-EGFR antibody or an antigen-binding fragment thereof claim 1 , comprising:at least one heavy chain complementarity determining region selected from the group consisting of a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 109, a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 110, and a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 111;at least one light chain complementarity determining region selected from the group consisting of a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 112, a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 113, and a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 114; ora combination of the at least one heavy chain complementarity determining region and the at least one light chain complementarity determining region.4. The anti-EGFR antibody or an antigen-binding fragment thereof according to claim 3 , comprising:a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 115 or SEQ ID NO: 117,a light chain variable region comprising the amino acid sequence of SEQ ID NO: 116 or SEQ ID NO: 118, ora combination thereof5. The anti-EGFR antibody or an antigen-binding fragment thereof according to claim 4 , wherein the anti-EGFR antibody or an antigen-binding fragment is an anti-EGFR scFv comprising:a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 115 or SEQ ID NO: 117,a light chain variable region comprising the amino acid sequence of ...

Подробнее
Номер записи: 8
29-01-2015 дата публикации

ANTI-ANG2 ANTIBODY

Номер: US20150030603A1
Автор: Han Sang Yeul, KIM Kyung Eun, LEE Hyo Seon, OH Seung Ja
Принадлежит:

An anti-Ang2 antibody or an antigen-binding fragment thereof that specifically binds to an angiogenesis-inducing factor Angiopoietin-2 (Ang2) and complexes with a Tie2 receptor and Ang2, and related methods and compositions. 1. An anti-Ang2 antibody or an antigen-binding fragment thereof which specifically binds to Angiopoietin-2 (Ang2) and forms a complex with a Tie2 receptor and Ang2.2. The anti-Ang-2 antibody or the antigen-binding fragment thereof according to claim 1 , which specifically binds to Q418 claim 1 , P419 claim 1 , or a combination of Q418 and P419 of human Ang2 (SEQ ID NO: 11); or 2 to 20 contiguous amino acid residues of human Ang2 (SEQ ID NO; 11) including Q418 claim 1 , P419 claim 1 , or the combination of Q418 and P419 in SEQ ID NO: 11.3. The anti-Ang-2 antibody or the antigen-binding fragment thereof according to claim 1 , comprisingat least one heavy chain complementarity determining region (CDR) selected from the group consisting of a polypeptide (CDR-H1) comprising the amino acid sequence of SEQ ID NO: 1, a polypeptide (CDR-H2) comprising the amino acid sequence of SEQ ID NO: 2, and a polypeptide (CDR-H3) comprising the amino acid sequence of SEQ ID NO: 3;at least one light chain complementarity determining region selected from the group consisting of a polypeptide (CDR-L1) comprising the amino acid sequence of SEQ ID NO: 4, a polypeptide (CDR-L2) comprising the amino acid sequence of SEQ ID NO: 5, and a polypeptide (CDR-L3) comprising the amino acid sequence of SEQ ID NO: 6; ora combination of said at least one heavy chain complementarity determining region and said at least one light chain complementarity determining region.4. The anti-Ang-2 antibody or the antigen-binding fragment thereof according to claim 3 , comprisingheavy chain complementarity determining regions comprising a polypeptide (CDR-H1) comprising the amino acid sequence of SEQ ID NO: 1, a polypeptide (CDR-H2) comprising the amino acid sequence of SEQ ID NO: 2, and a ...

Подробнее
Номер записи: 9
07-02-2019 дата публикации

USE OF IL-31 MONOCLONAL ANTIBODIES FOR TREATING PRURITUS

Номер: US20190038743A1
Автор: Bilsborough Janine M., Rene Shirley A., Siadak Anthony W.
Принадлежит:

Novel compositions derived from antigen-binding sites of immunoglobulins having affinity for IL-31 are provided. The compositions exhibit immunological binding properties of antibody molecules capable of binding specifically to a human IL-31. CDR regions derived from same or different immunoglobulin moieties are provided. Also provided are single chain polypeptides wherein Vand Vdomains are attached. The sFv molecules can include ancillary polypeptide moieties which can be bioactive, or which provide a site of attachment for other useful moieties. The compositions are useful in specific binding assays, affinity purification schemes, drug or toxin targeting, imaging, and genetic or immunological therapeutics for inflammatory diseases. The invention thus provides novel polypeptides, the DNAs encoding those polypeptides, expression cassettes comprising those DNAs, and methods of inducing the production of the polypeptides. The invention further provides the amino acid sequences of the variable regions of the monoclonal antibodies and use of these monoclonal antibody or antibody fragment in conjunction with an human IgG4 Fc molecule. 1. A method of reducing IL-31-induced pruritus in a human comprising administering to the human a therapeutically effective amount of a composition comprising a monoclonal antibody that specifically binds to a polypeptide consisting of amino acid residues 27-164 of SEQ ID NO:2 , and a pharmaceutically acceptable carrier;wherein the monoclonal antibody is a humanized monoclonal antibody derived from the antibody produced by the hybridoma deposited with the American Type Culture Collection having the ATCC Patent Deposit Designation PTA-6815;wherein the monoclonal antibody comprises a human IgG4 heavy chain immunoglobulin constant domain having a Serine to Proline mutation at Kabat position 241;wherein the monoclonal antibody is administered subcutaneously or intervenously to the human; andwherein after administration the pruritus is reduced.2 ...

Подробнее
Номер записи: 10
26-02-2015 дата публикации

MONOCLONAL ANTIBODIES THAT BIND B7H6 AND USES THEREOF

Номер: US20150056214A1
Автор: Baratin Myriam, Pierres Michel, Vivier Eric
Принадлежит:

Disclosed are monoclonal antibodies that specifically bind to the B7 family member B7H6, including antibodies capable of inhibiting the interaction of B7H6 with NKp30. Also disclosed are anti-B7H6 antibody-drug conjugates comprising an anti-B7H6 monoclonal antibody conjugated to a therapeutic agent. The anti-B7H6 antibodies and antibody-drug conjugates are useful in methods for exerting therapeutic effects against B7H6-expressing cells, as well as in diagnostic methods for the detection of B7H6 or B7H6-expressing cells. 154-. (canceled)55. A method for decreasing human natural killer (NK) cell activity against a cell expressing human B7H6 , comprising contacting a cell expressing human B7H6 , in the presence of a human NK cell , with an effective amount of an antibody , or antigen binding portion thereof , wherein the antibody:(a) binds to the same epitope on human B7H6 as an antibody produced by the hybridoma of clone designation number 4E5.5 (Deposit No. CNCM 1-4242) or number 17B1.3 (Deposit No. CNCM I-4245);(b) comprises the heavy and light chain CDR sequences, or the heavy and light chain variable region sequences, of an antibody produced by the hybridoma of clone designation number 4E5.5 or number 17B1.3; or(c) is produced by the hybridoma of clone designation number 4E5.5 or number 17B1.3, or an antigen-binding fragment thereof.56. A method for treating bone marrow cell (BMC) allograft rejection in a subject , comprising administering to the subject an effective amount of an antibody , or antigen binding portion thereof , wherein the antibody:(a) binds to the same epitope on human B7H6 as an antibody produced by the hybridoma of clone designation number 4E5.5 (Deposit No. CNCM I-4242) or number 17B1.3 (Deposit No. CNCM I-4245);(b) comprises the heavy and light chain CDR sequences, or the heavy and light chain variable region sequences, of an antibody produced by the hybridoma of clone designation number 4E5.5 or number 17B1.3; or(c) is produced by the ...

Подробнее
Номер записи: 11
05-03-2015 дата публикации

NEUTRALIZING ANTIBODY FOR EPSTEIN BARR VIRUS-ASSOCIATED DISEASE

Номер: US20150064174A1
Автор: Fogg Mark H., Wang Frederick C.S.
Принадлежит: THE BRIGHAM AND WOMEN'S HOSPITAL, INC.

Described herein are compositions, methods, and uses relating to an EBV-neutralizing antibody. 1. A composition comprising a purified , recombinant , humanized EBV-neutralizing antibody.57.-. (canceled)8. A method for preventing infectious mononucleosis in a subject suffering from genetic immunodeficiency comprising administering to the subject a pharmaceutical composition comprising a purified claim 1 , recombinant claim 1 , humanized EBV-neutralizing antibody of .1011-. (canceled)12. A method of preventing EBV-induced lymphoproliferative disease in immunosuppressed subjects claim 1 , the method comprising administering to the subject a pharmaceutical composition comprising a purified claim 1 , recombinant claim 1 , humanized EBV-neutralizing antibody of .13. A method of treating or preventing B-lymphoproliferative disease in immunosuppressed subjects claim 1 , the method comprising administering to the subject a pharmaceutical composition comprising a purified claim 1 , recombinant claim 1 , humanized EBV-neutralizing antibody of . This application claims benefit under 35 U.S.C. §119(e) of U.S. Provisional Application No. 61/604,574 filed Feb. 29, 2012, the contents of which are incorporated herein by reference in their entirety.The present invention was made with support from the Federal Government under Grant No. RO1 DE18926, awarded by the National Institutes of Health. The U.S. Government has certain rights in the invention.The instant application contains a Sequence Listing which has been submitted in ASCII format via EFS-Web and is hereby incorporated by reference in its entirety. Said ASCII copy, created on Jan. 3, 2013, is named 43214733.txt and is 33,730 bytes in size.The present invention relates to neutralizing antibodies targeting Epstein Barr virus (EBV), and compositions and methods comprising such antibodies useful in treating or preventing EBV-associated diseases.Epstein-Ban virus (EBV) is a herpesvirus (human herpesvirus 4) that infects nearly all ...

Подробнее
Номер записи: 12
05-03-2015 дата публикации

FIBROSIS SUPPRESSION BY INHIBITING INTEGRIN ALPHA-8 BETA-1 FUNCTION

Номер: US20150064187A1
Автор: Nishimichi Norihisa, Yokosaki Yasuyuki
Принадлежит:

Novel and effective anti-fibrosis agents are obtained. An anti-fibrosis agent containing an antagonist for integrin α is used. In addition, used is an antagonist containing an anti-integrin α antibody that specifically binds to at least one amino acid in a cap subdomain of an integrin α8 chain and a periphery thereof. Also, used is an anti-fibrosis agent containing an anti-integrin α antibody that specifically binds to R120 of an integrin α8 chain and a periphery thereof or S132 and a periphery thereof. Note that the above antagonists may each be an anti-integrin α antibody capable of binding to any of integrins α derived from a human, mouse, and rat. 110-. (canceled)11. A method of treating fibrosis comprising administering to a subject an anti-integrin α8β1 antibody that specifically binds to R120 of an integrin α8 chain and a periphery thereof or S132 and a periphery thereof and inhibits binding of integrin α8β1 to a ligand.12. The method of treating fibrosis according to claim 11 , wherein the anti-integrin α8β1 antibody is an anti-integrin α8β1 antibody capable of binding to any of integrins α8β1 derived from a human claim 11 , mouse claim 11 , and rat.13. The method of treating fibrosis according to claim 11 , wherein the anti-integrin α8β1 antibody is an anti-integrin α8β1 antibody that does not bind to at least one cap subdomain mutant of the integrin α8 chain while binding to a wild type of the integrin α8 chain.14. The method of treating fibrosis according to claim 11 , wherein the anti-integrin α8β1 antibody is an anti-integrin α8β1 antibody that does not bind to a R120K mutant or S132A mutant of the integrin α8 chain while binding to a wild type of the integrin α8 chain.15. The method of treating fibrosis according to claim 11 , wherein the anti-integrin α8β1 antibody is a monoclonal antibody.16. The method of treating fibrosis according to claim 11 , wherein the anti-integrin α8β1 antibody is an antigen-binding fragment.17. A method of treating a ...

Подробнее
Номер записи: 13
23-04-2015 дата публикации

COMPOSITION FOR MODULATING THE EXPRESSION OF CELL ADHESION MOLECULES

Номер: US20150110790A1
Автор: Adair Charles David, WANG Yuping
Принадлежит:

A composition is provided for modulating or attenuating the cytokine induced cell surface expression of cell adhesion molecules, comprising an antibody that binds digoxin. There is also provided a method of modulating or attenuating the cytokine induced cell surface expression of a cell adhesion molecule in a patient by administering to a digoxin antibody composition to a patient in need of such treatment. 120-. (canceled)21. A method for attenuating TNF-α induced expression of a cell adhesion molecule comprising:providing a mammalian cell;contacting the cell with a digoxin antibody composition; andcontacting the cell with a composition comprising TNF-α in an amount sufficient to induce the cell to express a cell adhesion molecule.22. The method of claim 21 , wherein the cell is an endothelial cell.23. The method of claim 21 , wherein the cell adhesion molecule comprises ICAM claim 21 , VCAM or E-selectin.24. The method of claim 21 , wherein the expression of the cell adhesion molecule comprises cell surface expression.25. A method for attenuating cellular expression of a cell adhesion molecule in a mammal exhibiting a pro-inflammatory effect of TNF-α claim 21 , comprising administering to the mammal a digoxin antibody composition in an amount sufficient to reduce cellular expression of the cell adhesion molecule.26. The method of claim 25 , wherein the cell is an endothelial cell.27. The method of claim 25 , wherein the cell adhesion molecule comprises ICAM claim 25 , VCAM or E-selectin28. The method of claim 25 , wherein the mammal's serum level of TNF-α is at least 1.0 pg/ml.29. The method of claim 25 , wherein the digoxin antibody composition is administered in an amount at least equal to the mammal's serum level of TNF-α.30. The method of claim 25 , wherein the digoxin antibody composition comprises between 0.001 mg and 500 mg digoxin binding capacity per kg of the mammal's weight.31. The method of claim 25 , wherein the pro-inflammatory effect of TNF-α is a ...

Подробнее
Номер записи: 14
14-05-2015 дата публикации

TREATMENT OF CANCER

Номер: US20150132226A1
Автор: Greenwood John, Moss Stephen, Wang Xiaomeng
Принадлежит:

This invention relates to the field of molecular physiology. Specifically, this invention relates to the prevention and/or treatment of cancer. Leucine-rich alpha-2-glycoprotein (Lrg1) has been demonstrated to be expressed in a range of cancer cells. Antagonists of Lrg1 can be used to prevent and/or treat cancer by an effect on neoplastic cells. 129-. (canceled)30. A method of treatment of cancer by an effect on neoplastic cells comprising:administering to a patient in need thereof an effective amount of an antagonist of Lrg1, wherein the effect on neoplastic cells is the down-regulation of neoplastic cell proliferation.31. (canceled)32. A method of treatment of cancer by an effect on tumour environment immune cell function comprising administering to a patient in need thereof an effective amount of an antagonist of Lrg1.33. A method according to claim 30 , wherein said antagonist acts on non-vascular cells.34. A method according to claim 30 , wherein the Lrg1 antagonist has at least one additional effect on neoplastic cells selected from:(a) down-regulation of neoplastic cell migration;(b) down-regulation of cell-cell interactions between neoplastic cells;(c) down-regulation of expression of neoplastic genes by neoplastic cells; and(d) blocking the switch of TGFβ from an anti- to a pro-oncogenic factor for neoplastic cells.35. A method according to claim 32 , wherein said antagonist decreases the percentage of CD14 positive CD11b positive cells within a peripheral blood mononuclear cell (PBMC) population compared to a control in which the antagonist is not administered.36. A method according to claim 32 , wherein said antagonist increases the percentage of RORγt positive CD4 T cells compared to a control in which the antagonist is not administered.37. A method according to claim 30 , wherein said antagonist blocks the interaction between:(a) Lrg1 and TGFβ Receptor II (TGFβRII); and/or(b) Lrg1 and TGFβ and/or(c) Lrg1 and an activin receptor-like kinase (ALK) and/or( ...

Подробнее
Номер записи: 15
07-08-2014 дата публикации

MONOVALENT BINDING PROTEINS

Номер: US20140221622A1
Автор: Ghayur Tariq, GU Jijie
Принадлежит: ABBVIE, INC.

Engineered monovalent binding proteins that bind to one or more ligands (such as an antigen) via one binding domain are provided, along with methods of making and uses in the prevention, diagnosis, and/or treatment of disease. 1. A binding protein comprising four polypeptide chains ,wherein two of said four polypeptide chains comprise VDH-(X1)n-C—(X2)n, wherein VDH is a heavy chain variable domain,X1 is a linker with the proviso that it is not CH1,C is a heavy chain constant domain,X2 is an Fc region,n is 0 or 1;andwherein two of said four polypeptide chains comprise VDL-(X3)n-C—(X4)n, whereinVDL is a light chain variable domain,X3 is a linker with the proviso that it is not CH1,C is a light chain constant domain,X4 does not comprise an Fc region; 'wherein at least one of said four polypeptide chains comprises a mutation, said mutation being located in the variable domain, wherein said mutation inhibits the targeted binding between the specific antigen and the mutant binding domain.', 'n is 0 or 1;'}2. The binding protein of claim 1 , wherein the Fc region of the two polypeptide chains having a formula of VDH-(X1)n-C—(X2)n each comprises a mutation claim 1 , wherein said mutations on the two Fc regions enhance heterodimerization of the two polypeptide chains.3. The binding protein of claim 1 , wherein one of the four polypeptide chains has a sequence identical to a polypeptide chain selected from the group consisting of SEQ ID Nos. 13-18.4. A binding protein comprising four polypeptide chains claim 1 ,wherein two of said four polypeptide chains comprise VDH1-(X1)n-VDH2-C—(X2)n, whereinVDH1 is a first heavy chain variable domain,VDH2 is a second heavy chain variable domain,C is a heavy chain constant domain,X1 is a linker with the proviso that it is not CH1,X2 is an Fc region,n is 0 or 1;andwherein two of said four polypeptide chains comprise VDL1-(X3)n-VDL2-C—(X4)n, whereinVDL1 is a first light chain variable domain,VDL2 is a second light chain variable domain,C is ...

Подробнее
Номер записи: 16
04-06-2015 дата публикации

THERAPIES FOR CANCER USING RLIP76

Номер: US20150152175A1
Автор: Awasthi Sanjay, Singhal Sharad S., YADAV Sushma
Принадлежит:

The present invention is a composition identified as a region of ralA binding protein 1, wherein the region neighbors a membrane-associated portion of the ralA binding protein 1, reduces transport activity and membrane association of the ralA binding protein 1 and kills cells undergoing uncontrolled cell growth in a subject that has cells undergoing uncontrolled cell growth. The region is used to generate medicines that kill malignant cells and tumorigenic cells. Medicines may be in the form of antibodies, si-RNA and small molecules that recognize the region. 130-. (canceled)31. A method of inhibiting growth of a malignant cell comprising contacting the malignant cell with an agent effective to inhibit transport activity of RLIP76 in the malignant cell , wherein the malignant cell exhibits an increased expression level of RLIP76 protein relative to a non-malignant cell.32. The method of claim 31 , wherein the agent is an antibody that binds specifically to the RLIP76 protein.33. The method of claim 32 , wherein the antibody binds specifically to an epitope on the RLIP76 protein claim 32 , wherein the epitope is expressed on the cell surface.34. The method of claim 32 , wherein the antibody binds specifically to a region of RLIP76 consisting essentially of the amino acids of SEQ ID NO:3 or SEQ ID NO:4.35. The method of claim 32 , wherein the antibody is in a composition comprising a pharmaceutically acceptable carrier.36. The method of claim 35 , wherein the composition comprises a liposome.37. The method of claim 31 , wherein the malignant cell is a melanoma cell claim 31 , a small cell lung carcinoma cell claim 31 , a non-small cell lung carcinoma cell claim 31 , an ovarian cancer cell claim 31 , a prostate cancer cell or an adenocarcinoma cell.38. The method of claim 31 , wherein the malignant cell is a melanoma cell.39. The method of claim 31 , wherein the malignant cell is in a subject.40. The method of claim 31 , wherein the malignant cell is in a human subject ...

Подробнее
Номер записи: 17
04-06-2015 дата публикации

Fc VARIANTS WITH ALTERED BINDING TO FcRn

Номер: US20150152183A1
Автор: Chamberlain Aaron, Dahiyat Bassil, Desjarlais John, Karki Sher Bahadur, Lazar Gregory
Принадлежит:

The present application relates to optimized IgG immunoglobulin variants, engineering methods for their generation, and their application, particularly for therapeutic purposes. 124-. (canceled)25. A polypeptide comprising a variant Fc region as compared to a parent Fc region , said variant Fc region comprising amino acid substitutions at position 434 , wherein said amino acid substitution is N434S , and wherein numbering is according to the EU Index in Kabat et al.26. A polypeptide according to claim 25 , wherein said polypeptide is a member selected from the group consisting of an antibody and an Fc fusion protein.27. A polypeptide according to claim 26 , wherein said polypeptide is an antibody.28. A polypeptide according to claim 27 , wherein said antibody is selected from the group consisting of a chimeric antibody claim 27 , a humanized antibody claim 27 , a monoclonal antibody claim 27 , and a human antibody.29. A polypeptide according to claim 26 , wherein said polypeptide is an Fc fusion protein.30. A method of producing a polypeptide according to claim 25 , said method comprising providing a cell comprising a nucleic acid encoding said polypeptide claim 25 , wherein said cell is cultured under conditions suitable for expression of said polypeptide.31. A method according to claim 30 , wherein said nucleic acid is contained in an expression vector.32. A host cell comprising a nucleic acid encoding a polypeptide according to .33. An expression vector claim 25 , wherein said expression vector encodes a polypeptide according to .34. An anti-C5 antibody comprising a variant Fc region as compared to a parent IgG Fc polypeptide claim 25 , wherein said variant Fc region comprises amino acid substitutions at position 434 claim 25 , wherein said amino acid substitution is N434S claim 25 , and wherein numbering is according to the EU Index in Kabat et al. This application is a continuation of U.S. patent application Ser. No. 11/932,151, filed Oct. 31, 2007 which claims ...

Подробнее
Номер записи: 18
21-08-2014 дата публикации

Compositions And Methods For Regulation Of Tumor Necrosis Factor-Alpha

Номер: US20140235829A1
Автор: Azam Tania, Dinarello Charles A., Kim Soo-Hyun
Принадлежит:

The present invention relates to compositions and methods relating to an interleukin 18-inducible cytokine termed tumor necrosis factor-alpha inducing factor (TAIF) or interleukin-32 (IL-32). In particular, the present invention provides compositions and methods for treating autoimmune diseases and cancer, in part by regulation of tumor necrosis factor-alpha expression. 118-. (canceled)19. An antibody , which binds to an IL-32 protein.20. The antibody of claim 19 , wherein said antibody is a monoclonal antibody.21. The antibody of claim 20 , wherein said monoclonal antibody comprises a Fab fragment.22. The antibody of claim 20 , wherein said monoclonal antibody is selected from the group consisting of 32-4 and 32-9.23. The antibody of claim 20 , wherein said monoclonal antibody is a humanized monoclonal antibody.24. The antibody of claim 20 , wherein said monoclonal antibody inhibits IL-32-induced TNFα production by a target cell.25. The antibody of claim 20 , wherein said monoclonal antibody inhibits IL-32-induced IKB degradation in a target cell.26. The monoclonal antibody of claim 20 , wherein said monoclonal antibody inhibits rapid IL-32-induced p38 MAF′K phosphorylation in a target cell.2744-. (canceled)45. The antibody of claim 19 , wherein said protein comprises the amino acid sequence set forth in SEQ ID NO:7.46. The antibody of claim 19 , wherein said antibody binds within a portion of exon 3 or exon 4 of said IL-32 protein. This invention was made in part with government support under grants AI-15614 and HL-68743, from the National Institutes Health. As such, the United States government has certain rights in the invention.The present invention relates to compositions and methods relating to an interleukin-18-inducible cytokine termed tumor necrosis factor-alpha inducing factor (TAIF) or interleukin-32 (IL-32). In particular, the present invention provides compositions and methods for treating autoimmune diseases and cancer, in part by regulation of tumor ...

Подробнее
Номер записи: 19
16-07-2015 дата публикации

Dosages of Immunoconjugates of Antibodies and SN-38 for Improved Efficacy and Decreased Toxicity

Номер: US20150196654A1
Автор: GOLDENBERG David M., Govindan Serengulam V.
Принадлежит:

The present invention relates to therapeutic immunoconjugates comprising SN-38 attached to an antibody or antigen-binding antibody fragment. The antibody may bind to EGP-1 (TROP-2), CEACAM5, CEACAM6, CD74, CD19, CD20, CD22, CSAp, HLA-DR, AFP or MUC5ac and the immunoconjugate may be administered at a dosage of between 4 mg/kg and 24 mg/kg, preferably 4, 6, 8, 9, 10, 12, 16 or 18 mg/kg. When administered at specified dosages and schedules, the immunoconjugate can reduce solid tumors in size, reduce or eliminate metastases and is effective to treat cancers resistant to standard therapies, such as radiation therapy, chemotherapy or immunotherapy. 1. A method of treating B-cell lymphoma or B-cell leukemia comprising administering to a human patient with B-cell lymphoma or B-cell leukemia an immunoconjugate comprising SN-38 conjugated to an hA20 (anti-CD20) antibody or antigen-binding fragment thereof; wherein the immunoconjugate is administered at a dosage of between 3 mg/kg and 18 mg/kg , wherein the patient has failed to respond to at least one other therapy , prior to treatment with the immunoconjugate.2. The method of claim 1 , wherein the dosage is selected from the group consisting of 3 mg/kg claim 1 , 4 mg/kg claim 1 , 6 mg/kg claim 1 , 8 mg/kg claim 1 , 9 mg/kg claim 1 , 10 mg/kg claim 1 , 12 mg/kg claim 1 , 16 mg/kg and 18 mg/kg.3. The method of claim 1 , wherein the cancer is a solid tumor and the treatment results in a reduction in tumor size of at least 15% claim 1 , at least 20% claim 1 , at least 30% claim 1 , or at least 40%.4. The method of claim 1 , wherein the cancer is metastatic.5. The method of claim 4 , further comprising reducing in size or eliminating the metastases.6. The method of claim 1 , wherein the cancer is refractory to other therapies but responds to the immunoconjugate.7. The method of claim 1 , wherein the patient has failed to respond to therapy with a camptothecin claim 1 , prior to treatment with the immunoconjugate.8. The method of ...

Подробнее
Номер записи: 20
16-07-2015 дата публикации

Dosages of Immunoconjugates of Antibodies and SN-38 for Improved Efficacy and Decreased Toxicity

Номер: US20150196662A1
Автор: GOLDENBERG David M., Govindan Serengulam V.
Принадлежит:

The present invention relates to therapeutic immunoconjugates comprising SN-38 attached to an antibody or antigen-binding antibody fragment. The antibody may bind to EGP-1 (TROP-2), CEACAM5, CEACAM6, CD74, CD19, CD20, CD22, CSAp, HLA-DR, AFP or MUC5ac and the immunoconjugate may be administered at a dosage of between 4 mg/kg and 24 mg/kg, preferably 4, 6, 8, 9, 10, 12, 16 or 18 mg/kg. When administered at specified dosages and schedules, the immunoconjugate can reduce solid tumors in size, reduce or eliminate metastases and is effective to treat cancers resistant to standard therapies, such as radiation therapy, chemotherapy or immunotherapy. 1. A method of treating B-cell lymphoma , B-cell leukemia , skin , esophageal , stomach , colon , rectal , pancreatic , lung , breast , ovarian , bladder , endometrial , cervical , testicular , melanoma , kidney , or liver cancer comprising administering to a human patient with B-cell lymphoma , B-cell leukemia , skin , esophageal , stomach , colon , rectal , pancreatic , lung , breast , ovarian , bladder , endometrial , cervical , testicular , kidney , or liver cancer an immunoconjugate comprising SN-38 conjugated to an hL243 (anti-HLA-DR) antibody or antigen-binding fragment thereof; wherein the immunoconjugate is administered at a dosage of between 3 mg/kg and 18 mg/kg , wherein the patient has failed to respond to at least one other therapy , prior to treatment with the immunoconjugate.2. The method of claim 1 , wherein the dosage is selected from the group consisting of 3 mg/kg claim 1 , 4 mg/kg claim 1 , 6 mg/kg claim 1 , 8 mg/kg claim 1 , 9 mg/kg claim 1 , 10 mg/kg claim 1 , 12 mg/kg claim 1 , 16 mg/kg and 18 mg/kg.3. The method of claim 1 , wherein the cancer is a solid tumor and the treatment results in a reduction in tumor size of at least 15% claim 1 , at least 20% claim 1 , at least 30% claim 1 , or at least 40%.4. The method of claim 1 , wherein the cancer is metastatic.5. The method of claim 4 , further comprising ...

Подробнее
Номер записи: 21
02-10-2014 дата публикации

ANTIBODIES THAT BIND TO OX40 AND THEIR USES

Номер: US20140294824A1
Автор: ATTINGER Antoine, BACK Jonathan Albert, Blein Stanislas, Hou Samuel, LISSILAA Rami
Принадлежит: Glenmark Pharmaceuticals S.A.

The present invention relates to antagonist antibodies or fragments thereof that bind to human OX40. More specifically, the present invention relates to an antagonist antibody or fragment thereof that binds to human OX40 comprising a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO: 1, and/or a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO: 2, and/or a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO: 3; and/or comprising a light chain CDR1 comprising the amino acid sequence of SEQ ID NO: 4, and/or a light chain CDR2 comprising the amino acid sequence of SEQ ID NO: 5 and/or a light chain CDR3 comprising the amino acid sequence of SEQ ID NO: 6. 173-. (canceled)74. A method for treating an OX40-mediated disorder in a subject in need thereof , the method comprising administering to the subject a therapeutically effective amount of an antagonistic antibody or fragment thereof that binds to human OX40 comprising a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO: 1 , a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO: 2 , a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO: 3; and/or comprising a light chain CDR1 comprising the amino acid sequence of SEQ ID NO: 4 , a light chain CDR2 comprising the amino acid sequence of SEQ ID NO: 5 and a light chain CDR3 comprising the amino acid sequence of SEQ ID NO: 6.75. The method of claim 74 , wherein the antibody or fragment thereof is a murine antibody claim 74 , chimeric antibody or a humanized antibody.76. The method of claim 74 , wherein the antibody or fragment thereof is a Humanized antibody.77. The method of claim 74 , wherein the antibody or fragment thereof comprises a heavy chain variable region sequence comprising the amino acid sequence of SEQ ID NO: 7.78. The method of claim 74 , wherein the antibody or fragment thereof comprises a non-CDR region of a heavy chain variable region sequence which is at least 80% identical ...

Подробнее
Номер записи: 22
02-10-2014 дата публикации

Hybrid constant regions

Номер: US20140294825A1
Автор: J. Yun Tso, Naoya Tsurushita
Принадлежит: JN Biosciences LLC

The invention provides hybrid constant regions and antibodies or fusion proteins incorporating the same. The hybrid constant regions include at least CH2 and CH3 regions of an IgG or IgA constant region and Cμ3 and Cμ4 regions of a Cμ constant region. The hybrids retain properties of both component constant regions. The hybrids retain the ability of a Cμ constant region to form multivalent complexes, e.g., pentameric or hexameric structures. IgG hybrids also retain IgG properties including pH-dependent FcRn binding, which is associated with a relatively long in vivo half-life, and specific binding to protein G, which facilitates purification. Depending on the isotype and subtype, the nature of the antigen and presence of additional IgG CH1 and hinge domains, IgG hybrids may also retain properties of specific binding to protein A, and effector functions ADCC, CDC and opsonization. IgA hybrids retain the property of IgA of binding to an Fc-alpha receptor CD89.

Подробнее
Номер записи: 23
09-10-2014 дата публикации

MULTISPECIFIC AND MULTIVALENT BINDING PROTEINS AND USES THEREOF

Номер: US20140302038A1
Автор: Bezabeh Binyam, Dimasi Nazzareno, Fleming Ryan, GAO CHANGSHOU
Принадлежит:

The disclosure generally provides proteins that bind two epitopes (e.g., a first and a second epitope) and that are bivalent for binding to each of the first and second epitopes. The disclosure also provides compositions comprising such proteins, nucleic acid molecules encoding such proteins and methods of making and using such proteins. 1. A protein , comprising:a Fab arm that binds to a first epitope,a binding domain (BD) that binds to a second epitope, and{'sub': H', 'H, 'an Fc region comprising C2 and C3 domains;'}wherein the BD is interconnected to the Fab arm via a first polypeptide linker (L1) and to the Fc region via a second polypeptide linker (L2); and wherein the protein is bivalent for binding to each of the first and second epitopes.2. The protein of claim 1 , wherein the L1 comprises 1-50 amino acid residues.3. The protein of or claim 1 , wherein the L2 comprises 1-50 amino acid residues.43. The protein of any of - claims 1 , wherein each of the L1 and the L2 comprises 1-50 amino acid residues.54. The protein of any of - claims 1 , wherein each of the L1 and the L2 comprises 15-30 amino acid residues.65. The protein of any of - claims 1 , wherein the L1 comprises a hinge portion and a linker portion.76. The protein of any of - claims 1 , wherein the L2 comprises a hinge portion and a linker portion.87. The protein of any of - claims 1 , wherein each of the L1 and the L2 comprises a hinge portion and a linker portion.98. The protein of any of - claims 1 , wherein the L1 comprises at least 5 amino acid residues of an antibody hinge region.109. The protein of any of - claims 1 , wherein the L2 comprises at least 5 amino acid residues of an antibody hinge region.1110. The protein of any of - claims 1 , wherein the L1 comprises at least 7 amino acid residues of an antibody hinge region.1211. The protein of any of - claims 1 , wherein the L2 comprises at least 7 amino acid residues of an antibody hinge region.1312. The protein of any of - claims 1 , wherein ...

Подробнее
Номер записи: 24
13-08-2015 дата публикации

COMPOSITION COMPRISING A MIXTURE OF CD95-FC ISOFORMS

Номер: US20150225475A1
Автор: Gieffers Christian, Hill Oliver, Thiemann Meinolf
Принадлежит: Apogenix GmbH

The present invention relates to a composition comprising a mixture of fusion protein isoforms, each fusion protein comprising an extracellular CD95 domain or a functional fragment thereof or an Fc domain or functional fragment thereof, formulations providing such composition in a stable form as well as a method for producing such a composition. 1. A composition comprising a mixture of fusion protein isoforms , each fusion protein comprising at least an extracellular CD95 domain or a functional fragment thereof and at least a Fc domain or a functional fragment thereof distributing within a pI range of 4.0-8.5.2. The composition according to claim 1 , wherein the Fc domain is a human Fc domain.3. The composition according to claim 1 , wherein the fusion protein is APG101 claim 1 , a polypeptide having at least 70% identity to APG101 and/or a functional fragment of APG101.4. The composition according to claim 1 , wherein the pI range is 4.5-7.8.5. The composition according to claim 1 , comprising 0.0-5.0 mol % of fusion protein high molecular weight forms of dimers and/or aggregates.6. The composition according to claim 1 , comprising high amounts of sialic acids.7. The composition according to claim 3 , comprising N-terminally shortened fusion proteins.8. The composition according to claim 1 , wherein the Fc domain or functional fragment thereof is N-linked glycosylated.9. The composition according to claim 1 , comprising N-terminally blocked fusion proteins.10. The composition according to claim 1 , comprising 80-99 mol % N-terminally blocked fusion proteins and/or 1-20 mol % fusion proteins having a free N-terminus.11. (canceled)12. A formulation comprising the composition of claim 1 , further comprising(a) phosphate,(b) a viscosity enhancing agent, and/or(c) having a pH value in the range of 4-8.13. (canceled)14. A method for producing a composition according to claim 1 , comprising the steps of:(a) producing a composition comprising a mixture of fusion protein ...

Подробнее
Номер записи: 25
06-11-2014 дата публикации

Antibodies for Molecular Imaging of Vulnerable Plaques in Atherosclerosis

Номер: US20140328753A1
Автор: Bonetto Stephane, CLOFENT-SANCHEZ Gisèle, Deramchia Kamel, Joacobin Marie-Josee, Traineau Jeanny
Принадлежит:

Antibodies for molecular imaging of vulnerable plaques in atherosclerosis Antibody specifically binding to atherosclerosis lesions for in vivo imaging and methods for in vivo imaging of atherosclerosis lesions in a patient. 1. Antibody specifically binding to atherosclerosis lesions wherein said antibody or antibody fragment comprises at least a VH CDR1 comprising the amino acid sequence of SEQ ID No. 1 , a VH CDR2 comprising the amino acid sequence of SEQ ID No. 2 , a VL CDR1 comprising the amino acid sequence of SEQ ID No. 3 and a VL CDR2 comprising the amino acid sequence of SEQ ID No. 4; and comprising at least:a VH CDR3 comprising the amino acid sequence of SEQ ID No. 5 and a VL CDR3 comprising the amino acid sequence of SEQ ID No. 6, ora VH CDR3 comprising the amino acid sequence of SEQ ID No. 10 and a VL CDR3 comprising the amino acid sequence of SEQ ID No. 11, ora VH CDR3 comprising the amino acid sequence of SEQ ID No. 15 and a VL CDR3 comprising the amino acid sequence of SEQ ID No. 16, ora VH CDR3 comprising the amino acid sequence of SEQ ID No. 20 and a VL CDR3 comprising the amino acid sequence of SEQ ID No. 21, ora VH CDR3 comprising the amino acid sequence of SEQ ID No. 25 and a VL CDR3 comprising the amino acid sequence of SEQ ID No. 26, ora VH CDR3 comprising the amino acid sequence of SEQ ID No. 30 and a VL CDR3 comprising the amino acid sequence of SEQ ID No. 31, ora VH CDR3 comprising the amino acid sequence of SEQ ID No. 35 and a VL CDR3 comprising the amino acid sequence of SEQ ID No. 36.2. The Aantibody according to comprising at least:a VH domain comprising the amino acid sequence of SEQ ID No. 7 and a VL domain comprising the amino acid sequence of SEQ ID No. 8, ora VH domain comprising the amino acid sequence of SEQ ID No. 12 and a VL domain comprising the amino acid sequence of SEQ ID No. 13, ora VH domain comprising the amino acid sequence of SEQ ID No. 17 and a VL domain comprising the amino acid sequence of SEQ ID No. 18, ora VH domain ...

Подробнее
Номер записи: 26
06-11-2014 дата публикации

MITIGATION OF DISEASE BY INHIBITION OF GALECTIN-12

Номер: US20140328847A1
Автор: Hsu Daniel K., Liu Fu-Tong, Yang Ri-Yao, Yu Lan
Принадлежит: The Regents of the University of California

It has now been discovered that mice with an ablated galectin-12 gene exhibit enhanced fat mobilization (lipolysis), have reduced adipose tissue mass, improved insulin sensitivity and glucose tolerance, and increased mitochondrial respiration. Inhibition of galectin-12 activity can therefore be used to reduce, mitigate, inhibit and/or prevent obesity, type 2 diabetes, metabolic diseases, mitochondrial diseases, other disease conditions associated with and/or caused by the abnormal expression or overexpression of galectin-12, and other disease conditions with normal galectin-12 expression but will benefit from galectin-12 inhibition. 1. A method of promoting lipolysis and/or reducing adiposity in a subject , comprising administering to the subject an effective amount of an inhibitor of galectin-12 activity , thereby promoting lipolysis and/or reducing adiposity in the subject.2. A method of promoting and/or increasing insulin sensitivity and/or glucose tolerance in a subject , comprising administering to the subject an effective amount of an inhibitor of galectin-12 activity , thereby promoting and/or increasing insulin sensitivity and/or glucose tolerance in the subject.3. The method of claim 1 , wherein the subject is obese.4. The method of claim 1 , wherein the subject has type 2 diabetes.5. The method of claim 1 , wherein the subject has metabolic disease.6. The method of claim 1 , wherein the subject has cardiovascular disease.7. (canceled)8. A method of preventing claim 1 , inhibiting claim 1 , mitigating claim 1 , or delaying one or more symptoms of a mitochondrial disease in a subject claim 1 , comprising administering to the subject an effective amount of an inhibitor of galectin-12 activity claim 1 , thereby preventing claim 1 , inhibiting claim 1 , mitigating claim 1 , or delaying one or more symptoms of the mitochondrial disease by promoting and/or increasing mitochondrial respiration in the subject.9. (canceled)10. The method of claim 8 , wherein the ...

Подробнее
Номер записи: 27
06-11-2014 дата публикации

HUMAN IMMUNODEFICIENCY VIRUS NEUTRALIZING ANTIBODIES AND METHODS OF USE THEREOF

Номер: US20140328862A1
Автор: Bjorkman Pamela J., Diskin Ron, Nussenzweig Michel, Scheid Johannes
Принадлежит:

The invention provides broadly neutralizing antibodies directed to epitopes of Human Immunodeficiency Virus, or HIV. The invention further provides compositions containing HIV antibodies used for prophylaxis, and methods for diagnosis and treatment of HIV infection. 1. An isolated HIV antibody comprising one or both of a heavy chain comprising the consensus amino acid sequence of SEQ ID NO:1 and a light chain comprising the consensus amino acid sequence of SEQ ID NO:2.2. The isolated HIV antibody of wherein the antibody neutralizes HIV virus ZM53M.PB12 at an ICconcentration of less than 1.0 μg/ml claim 1 , or HIV virus R1166.c1 at an ICconcentration of less than 1.0 μg/ml claim 1 , or DU172.17 at an ICconcentration of less than 30 μg/ml.3. The isolated HIV antibody of wherein the antibody neutralizes a VRC01-resistant HIV virus at an ICconcentration of less than 30 μg/ml.4. An isolated HIV antibody selected from the group consisting of 3BNC117 claim 1 , 3BNC60 claim 1 , 12A12 claim 1 , 12A21 claim 1 , NIH45-46 claim 1 , bANC131 claim 1 , 8ANC134 claim 1 , IB2530 claim 1 , INC9 and 8ANC1965. An isolated HIV antibody comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 5-583.6. An isolated HIV antibody comprising at least one of insertion sequence SEQ ID No: 3 in the FR3 region of the heavy chain and insertion sequence SEQ ID No: 4 in the CDR3 region of the heavy chain.7. A method to improve the neutralization potency of an isolated HIV antibody comprising making an isolated HIV antibody comprising at least one of insertion sequence SEQ ID No: 3 in the FR3 region of the heavy chain and insertion sequence SEQ ID No: 4 in the CDR3 region of the heavy chain86. A composition comprising an isolated HIV antibody of any one of -.96. A nucleic acid molecule encoding the isolated HIV antibody of any one of -.10. A vector comprising the nucleic acid molecule of .11. A cell comprising the vector of .126. A pharmaceutical composition comprising at ...

Подробнее
Номер записи: 28
13-11-2014 дата публикации

Humanized Monoclonal Antibodies to Hepatocyte Growth Factor

Номер: US20140335076A1
Автор: Kim Kyung Jin, Park Hangil, Vasquez Maximiliano, Wang Lihong
Принадлежит: Galaxy Biotech, LLC

The present invention is directed toward a humanized neutralizing monoclonal antibody to hepatocyte growth factor, a pharmaceutical composition comprising same, and methods of treatment comprising administering such a pharmaceutical composition to a patient. 129-. (canceled)30. A method of measuring the level of HGF in a tumor , the method comprising staining a tumor biopsy with a humanized anti-HGF monoclonal antibody wherein the monoclonal antibody comprises mature variant light and heavy chain V region sequences that are at least 90% identical to the respective HuL2G7 mature light and heavy chain V regions and binds HGF.31. The method of wherein the antibody is labeled.32. A method of measuring the level of HGF in the circulation of a patient with a tumor claim 31 , the method comprising combining serum from the patient with a humanized anti-HGF monoclonal antibody wherein the monoclonal antibody comprises mature variant light and heavy chain V region sequences that are at least 90% identical to the respective HuL2G7 mature light and heavy chain V regions and binds HGF.33. The method of wherein the antibody is labeled.34. A kit for measuring HGF in a patient sample claim 32 , comprising a fluorescently labeled humanized anti-HGF monoclonal antibody wherein the monoclonal antibody comprises mature variant light and heavy chain V region sequences that are at least 90% identical to the respective HuL2G7 mature light and heavy chain V regions and binds HGF.35. A method of purifying HGF by affinity chromatography claim 32 , the method comprising combining a sample containing HGF to immobilized humanized anti-HGF monoclonal antibody under conditions in which the HGF is specifically bound by the antibody claim 32 , removing unbound material claim 32 , and recovering the bound HGF claim 32 , wherein the monoclonal antibody comprises mature variant light and heavy chain V region sequences that are at least 90% identical to the respective HuL2G7 mature light and heavy ...

Подробнее
Номер записи: 29
13-11-2014 дата публикации

Treatment For Rheumatoid Arthritis

Номер: US20140335081A1
Автор: Alex GODWOOD, Fabio MAGRINI
Принадлежит: Medlmmune Ltd

Treatment of rheumatoid arthritis (RA) to provide clinical benefit in patients, including decrease in DAS28-CRP by more than 1.2 and/or improvement determined by ACR20, ACR50 or ACR70, comprising administering therapeutic antibody mavrilimumab or other inhibitor targeted to Tyr-Leu-Asp-Phe-Gln motif of granulocyte/macrophage colony stimulating factor receptor alpha (GM-CSFRα). Use of GM-CSFRα inhibitors such as mavrilimumab to enhance clinical benefit in RA patients receiving stable dose of DMARDs, particularly methotrexate.

Подробнее
Номер записи: 30
13-11-2014 дата публикации

MONOCLONAL ANTIBODY AGAINST INTERFERON-GAMMA (IFN-GAMMA) INDUCING FACTOR (IFIG, IL-18)

Номер: US20140336364A1
Автор: KOHNO Keizo, KUNIKATA Toshi, KURIMOTO Masashi, OKAMURA Haruki, TANIGUCHI Mutsuko, TANIMOTO Tadao, TORIGOE Kakuji
Принадлежит:

A protein which induces the IFN-γ production by immunocompetent cells and has a molecular weight of 19,000±5,000 daltons on SDS-PAGE or gel filtration method and a pI of 4.8±1.0 on chromatofocusing. The protein is isolated from mouse liver and can be purified by a monoclonal antibody specific to it. The monoclonal antibody can be also used for assaying the protein. 1. A monoclonal antibody which specifically binds to IGIF or IL-18 consisting of the amino acid sequence of SEQ ID NO:2 , wherein Xaa is Met or Thr; which substantially adsorbs said IGIF or said IL-18 but does not substantially adsorb proteins other than said IGIF or said IL-18; and which affords a purified IGIF or IL-18 with a purity of at least 95% when used in immunoaffinity chromatography.2. A monoclonal antibody , which is obtainable by immunizing mammals using a protein consisting of the amino acid sequence of SEQ ID NO:2 , wherein Xaa is Met or Thr , or an antigenic fragment thereof as an antigen ,collecting antibody-producing cells from the mammals,hybridizing thus collected antibody-producing cells with cells that infinitely proliferate,cloning hybridomas capable of producing said antibody,culturing the clones in nutrient culture media, andcollecting the monoclonal antibody from the resultant cultures.3. A process for preparing a monoclonal antibody , which comprises the steps of:immunizing mammals using a protein consisting of the amino acid sequence of SEQ ID NO:2, wherein Xaa is Met or Thr, or an antigenic fragment thereof as an antigen;collecting antibody-producing cells from the mammals;hybridizing thus collected antibody-producing cells with cells that infinitely proliferate;cloning hybridomas capable of producing said antibody;culturing the clones in nutrient culture media; andcollecting the monoclonal antibody from the resultant cultures.4. A kit for detecting the presence of IGIF or IL-18 in a sample claim 1 , which comprises a monoclonal antibody of labeled with radioactive substance ...

Подробнее
Номер записи: 31
17-09-2015 дата публикации

ANTIBODIES TO IL-6 AND USE THEREOF

Номер: US20150259413A1
Автор: Anderson Katie, Carvalho Jensen Anne Elisabeth, Dutzar Benjamin H., Garcia-Martinez Leon, Kovacevich Brian R., Latham John, Ojala Ethan W., Smith Jeffrey T.L.
Принадлежит:

The present invention is directed to antibodies and fragments thereof and humanized versions thereof having binding specificity for IL-6. Another embodiment of this invention relates to the antibodies described herein, and binding fragments thereof, comprising the sequences of the V, V, and CDR polypeptides described herein, and the polynucleotides encoding them. The invention also contemplates conjugates of anti-IL-6 antibodies and binding fragments thereof conjugated to one or more functional or detectable moieties. The invention also contemplates methods of making said anti-IL-6 antibodies and binding fragments thereof. Embodiments of the invention also pertain to the use of anti-IL-6 antibodies, and binding fragments thereof, for the diagnosis, assessment and treatment of diseases and disorders associated with IL-6. These antibodies may bind at least one of soluble IL-6, cell surface expressed IL-6, IL-6/IL-6R and/or prevent the association of IL-6 and IL-6R, the association of IL-6/IL-6R and gp130 and or the formation of IL-6/IL-6R/gp130 multimers and thereby inhibit a biological effect associated with any of the foregoing. 1137-. (canceled)138. A vector that encodes for an anti-human IL-6 antibody or antigen-binding fragment wherein the anti-human IL-6 antibody or antibody fragment comprises: a variable light (V) region comprising complementarity region CDR1 , CDR2 and CDR3 polypeptides , respectively having the sequences of SEQ ID NO:4 , 5 and 6 , and a variable heavy (V) region comprising complementarity region CDR1 , CDR2 and CDR3 polypeptides , respectively having the sequences of SEQ ID NO:7 , 8 or 120 and 9.139. The vector of claim 138 , wherein the Vregion comprises CDR1 claim 138 , CDR2 and CDR3 polypeptides claim 138 , respectively having the sequences of SEQ ID NO:4 claim 138 , 5 and 6 claim 138 , and the Vregion comprises CDR1 claim 138 , CDR2 and CDR3 polypeptides claim 138 , respectively having the sequences of SEQ ID NO:7 claim 138 , 120 and 9. ...

Подробнее
Номер записи: 32
20-11-2014 дата публикации

INACTIVATION OF SMOOTH MUSCLE TISSUE

Номер: US20140341801A1
Автор: AUTH David C., DANEK Christopher J., KAPLAN Gary, Laufer Michael D., Wizeman William
Принадлежит:

Treatment and procedures for treating bodily conduits involves deactivating, killing, or otherwise treating smooth muscle tissue of the conduit. 1. A method of reducing the ability of a lung airway to narrow , the method comprising:placing an effective amount of a muscle impairing agent into a blood vessel that supplies blood to tissue of the lung airway, where the muscle impairing agent affects the ability of the lung airway to constrict in response to a stimulus.247-. (canceled)48. The method of claim 1 , wherein the blood vessel comprises a bronchial artery.49. The method of claim 1 , wherein the agent includes one or more of an artificial toxin claim 1 , a naturally occurring toxin claim 1 , a radioactive agent claim 1 , a viral agent claim 1 , a drug claim 1 , Iodine 131 claim 1 , laser absorptive dyes claim 1 , an agent that binds to constituents of airway smooth muscle claim 1 , neutrophils claim 1 , paralytic agents claim 1 , and embolizing agents.50. The method of claim 1 , further comprising delivering a second agent to the body claim 1 , wherein the second agent protects a portion of the body against the effects of the agent.51. The method of claim 50 , wherein the second agent is delivered by a mode selected from the group consisting of inhalation claim 50 , injection claim 50 , and oral administration.52. The method of claim 1 , further comprising stimulating the lung airway.53. The method of claim 52 , wherein stimulating the lung airway increases absorption of the agent.54. The method of claim 52 , wherein placing the agent comprises injecting the agent in response to an amount of contraction of the airway caused by the stimulation.55. The method of claim 1 , further comprising selecting a second vascular site claim 1 , and reducing blood flow in the second vascular site to decrease the flow rate of the agent in the blood vessel.56. The method of claim 1 , further comprising monitoring the blood to determine an amount of the agent in the blood.57. A ...

Подробнее
Номер записи: 33
20-11-2014 дата публикации

PROVASOPRESSIN ANTAGONISTS AND USES THEREOF

Номер: US20140341802A1
Автор: North William G., Pang Roy H.L.
Принадлежит: WOOMERA THERAPEUTICS

Provided herein are pro-VP antagonists, such as antibodies and antigen-binding portions thereof specific for pro-VP, for identifying and targeting expressing cancer cells. Applicants additionally provide methods of using said compositions, for example to image cancer cells in vivo and in biological samples. The compositions may also be used for treating patients suffering from a provasopressin-expressing cancer. Provasopressin-expressing cancers include neuroendocrine cancer, pancreatic cancer, and prostate cancer. 1. A method of treating a provasopressin-expressing (pro-VP-expressing) cancer , comprising administering a therapeutically effective amount of a provasopressin-binding agent to a patient in need thereof , wherein the cancer is not small cell lung cancer (SCLC) or breast cancer.2. A method of treating a provasopressin-expressing (pro-VP-expressing) cancer , comprising administering , to a patient in need thereof , a therapeutically effective amount of a provasopressin-binding agent , and a therapeutically effective amount of a pharmaceutical composition comprising a chemotherapeutic agent.3. The method of claim 1 , wherein the cancer is a neuroendocrine cancer.4. The method of claim 1 , wherein the cancer is a prostate cancer.5. The method of claim 1 , wherein the cancer is a pancreatic cancer.6. The method of claim 2 , wherein the cancer is SCLC or breast cancer.7. The method of claim 3 , wherein the neuroendocrine cancer is a brain claim 3 , gastroenteric claim 3 , ovarian claim 3 , endomedrial claim 3 , testicular claim 3 , adrenal claim 3 , or skin cancer.8. The method of claim 1 , wherein the provasopressin-binding antibody is MAG-1 claim 1 , or a human antibody thereof claim 1 , or a humanized antibody thereof claim 1 , or a chimeric antibody thereof.9. The method of claim 1 , wherein the provasopressin-binding antibody binds to the VAG region of the pro-VP protein.10. The method of claim 1 , wherein the provasopressin-binding antibody is a mouse ...

Подробнее
Номер записи: 34
20-11-2014 дата публикации

Prevention and Treatment of Amyloidogenic Disease

Номер: US20140341911A1
Автор: Schenk Dale B.
Принадлежит:

The invention provides compositions and methods for treatment of amyloidogenic diseases. Such methods entail administering an agent that induces a beneficial immune response against an amyloid deposit in the patient. The methods are particularly useful for prophylactic and therapeutic treatment of Alzheimer's disease. In such methods, a suitable agent is Aβ peptide, active fragments thereof or an antibody thereto. 1. A method of preventing or treating a disease characterized by amyloid deposit in a patient , comprising administering an effective dosage of an antibody that specifically binds to the amyloid deposit or a component thereof to the patient.237-. (canceled)38. A method of preventing or treating Alzheimer's disease , comprising administering an effective dosage of a polypeptide comprising an active fragment of Aβ that induces an immune response to Aβ in the patient.3952-. (canceled)53. A pharmaceutical composition comprising an active fragment of Aβ effective to induce a response to AB in a patient and an adjuvant.5455-. (canceled) This application is a continuation of U.S. application Ser. No. 09/322,289, filed May 28, 1999, which is a continuation-in-part of U.S. application Ser. No. 09/201,430, filed Nov. 30, 1998 which claims the benefit under 35 U.S.C. 119(e) of U.S. Application No. 60/080,970, filed Apr. 7, 1998, and U.S. Application 60/067,740, filed Dec. 2, 1997, all of which are incorporated by reference in their entirety for all purposes.Alzheimer's disease (AD) is a progressive disease resulting in senile dementia. See generally Selkoe, 16, 403-409 (1993); Hardy et al., WO 92/13069; Selkoe, 53, 438-447 (1994); Duff et al., 373, 476-477 (1995); Games et al., 373, 523 (1995). Broadly speaking the disease falls into two categories: late onset, which occurs in old age (65+ years) and early onset, which develops well before the senile period, i.e, between 35 and 60 years. In both types of disease, the pathology is the same but the abnormalities tend ...

Подробнее
Номер записи: 35
20-11-2014 дата публикации

DNA ENCODING FUNCTION MODIFYING NAv1.7 ANTIBODIES

Номер: US20140342406A1
Автор: BAKER TERENCE SEWARD, de Ryck Marc Roger, FINNEY Helene Margaret, LAWSON ALASTAIR DAVID GRIFFITHS, Miller Karen Margrete, Wolff Christian Gilbert J.
Принадлежит: UCB PHARMA S.A.

A Na1.7 binding entity that after binding functionally modifies the activity of the ion channel, in particular an anti-Na1.7 antibody or binding fragment thereof, pharmaceutical compositions comprising said antibodies, use of the antibodies and compositions comprising the same, in treatment, for example in the treatment/modulation of pain and processes for generating and preparing said antibodies. 122-. (canceled)23. An isolated DNA encoding the heavy and/or light chain(s) of an anti-Na1.7 antibody or binding fragment thereof which , after binding the Na1.7 ion channel , is functionally modifying thereto such that the activity of the ion channel is reduced by at least 5 percent in an in vitro assay.2432. A cloning or expression vector comprising one or more DNA sequences according to , , or .25. A host cell comprising one or more cloning or expression vectors according to .26. A process for the production of an antibody having binding specificity for human Nav1.7 claim 25 , comprising culturing the host cell of and isolating the antibody.2730-. (canceled)31. The isolated DNA of claim 23 , wherein the heavy chain comprises a CDR having the sequence given in SEQ ID NO:28 or SEQ ID NO:40 or SEQ ID NO:82 for CDR-H1 claim 23 , a CDR having the sequence given in SEQ ID NO:29 or SEQ ID NO:41 or SEQ ID NO:83 for CDR-H2 and a CDR having the sequence given in SEQ ID NO:30 or SEQ ID NO:42 or SEQ ID NO:84 for CDR-H3.32. The isolated DNA of claim 23 , wherein the variable domain of the light chain comprises a CDR having the sequence given in SEQ ID NO:25 or SEQ ID NO:37 or SEQ ID NO:79 for CDR-L1 claim 23 , a CDR having the sequence given in SEQ ID NO:26 or SEQ ID NO:38 or SEQ ID NO:80 for CDR-L2 and a CDR having the sequence given in SEQ ID NO:27 or SEQ ID NO:39 or SEQ ID NO:81 for CDR-L3. The present application claims priority under 35 U.S.C. §119(a) to provisional application Ser. No. 61/255,202, Filed: Oct. 27, 2009, which is incorporated by reference herein in its entirety ...

Подробнее
Номер записи: 36
20-11-2014 дата публикации

IL-17 BINDING PROTEINS

Номер: US20140343267A1
Автор: Bryant Shaughn H., Clabbers Anca, HSIEH Chung-Ming, Hugunin Margaret, Kutskova Yuliya, Leddy Mary R., McRae Bradford L., Memmott John E., Murtaza Anwar, Perez Jennifer M., Tarcsa Edit, Wallace Craig, Zhong Suju
Принадлежит: AbbVie Inc.

Proteins that bind IL-17 and/or IL-17F are described along with there use in composition and methods for treating, preventing, and diagnosing IL-17 related diseases and for detecting IL-17 in cells, tissues, samples, and compositions. 1162-. (canceled)163. An isolated nucleic acid encoding a binding protein amino acid sequence , wherein the binding protein comprises a polypeptide chain , wherein the polypeptide chain comprises VD1-(X1)n-VD2-C-(X2)n , wherein;VD 1 is a first heavy chain variable domain;VD2 is a second heavy chain variable domain;C is a heavy chain constant domain;X1 is a linker with the proviso that it is not CH1;X2 is an Fc region; andn is 0 or 1;wherein the binding protein is capable of binding human IL-17 and TNF-α;wherein VD1 comprises an amino acid sequence of a variable heavy region (VH) of an anti-TNF-α antibody, wherein the amino acid sequence is any of SEQ ID NOs: 563, 573, 578, 593, 628, 638, 648, 658, 668, 678, 688, 698, 708, 718, 728, 738, 748, 758, 763, 773, 783, 793, 803, 813, 823, 833, 843, 853, 863, 873, and 883; andwherein VD2 comprises the amino acid sequence of a VH region of anti-IL-17 antibody, wherein the amino acid sequence is any of SEQ ID NOs:565, 575, 580, 595, 630, 640, 650, 660, 670, 680, 690, 700, 710, 720, 730, 740, 750, 760, 765, 775, 795, 805, 815, 825, 835, 845, 855, 865, 875, and 885.164. A vector comprising an isolated nucleic acid according to of .165. (canceled)166. A host cell comprising the vector of .167176-. (canceled)177. A method of producing a binding protein claim 166 , the method comprising culturing the host cell described in in culture medium under conditions sufficient to produce the binding protein.178. The method of claim 177 , wherein 50%-75% of the binding protein produced is a dual specific tetravalent binding protein.179201-. (canceled)202. An isolated nucleic acid encoding a binding protein amino acid sequence claim 177 , wherein the binding protein comprises a polypeptide chain claim 177 , ...

Подробнее
Номер записи: 37
27-11-2014 дата публикации

ANTIBODIES AGAINST HUMAN IL-12

Номер: US20140348847A1
Автор: Gately Maurice Kent, Presky David Howard
Принадлежит: HOFFMAN-LAROCHE, INC.

The present invention relates to novel p75 heterodimer specific anti-human IL-12 antibodies that are characterized by a higher potency and greater efficacy in neutralizing human IL-12 bioactivity than known heterodimer specific IL-12 monoclonal antibodies. The heterodimer specific antibodies recognize one or more epitopes of the human IL-12 p75 heterodimer, but do not bind to the p40 subunit alone. The heterodimer specific IL-12 antibodies neutralize rhesus monkey IL-12 bioactivity with a potency similar to their potency for neutralizing human IL-12 bioactivity making them useful IL-12 antagonists for in vivo studies in the rhesus monkey. 1. A method for producing an antibody that immunologically reacts with the human IL-12 p75 heterodimer which consists of a p35 subunit and a p40 subunit , comprising the steps of:(a) immunizing a mammal deficient in a gene encoding an IL-12 p35 subunit or an IL-12 p40 subunit with the human IL-12 p75 heterodimer to produce antibodies;(b) obtaining antibodies from the immunized mammal;(c) screening said antibodies for their ability to bind an epitope presented by the p75 heterodimer to obtain said binding antibody.2. A method for producing a monoclonal antibody that immunologically reacts with the human IL-12 p75 heterodimer which consists of a p35 subunit and a p40 subunit , comprising the steps of:(a) immunizing a mammal deficient in a gene encoding an IL-12 p35 subunit or an IL-12 p40 subunit with the human IL-12 p75 heterodimer to produce antibodies;(b) harvesting antibody producing cells from the immunized mammal;(c) forming a monoclonal antibody producing hybridoma from said cells and obtaining said monoclonal antibody;(d) screening said monoclonal antibody produced by said hybridoma for the ability to bind to an epitope presented by the p75 heterodimer to obtain said binding monoclonal antibody.3. The method of claim 2 , wherein the antibodies produced from the hybridoma are further screened and selected for their ability to ...

Подробнее
Номер записи: 38
04-12-2014 дата публикации

TARGETED BINDING AGENTS AGAINST B7-H1

Номер: US20140356353A1
Автор: ALIMZHANOV MARAT, BABCOCK JOHN, BOYLE MELANIE, CHODORGE MATTHIEU, Foltz Ian Nevin, Hammond Scott, KANG JASPAL SINGH, Morrow Michelle, MULGREW KATHLEEN ANN, QUEVA CHRISTOPHE, SEKIROV LAURA, STEWARD ROSS A.
Принадлежит:

Human monoclonal antibodies directed against B7-H1 and uses of these antibodies in diagnostics and for the treatment of diseases associated with the activity and/or expression of B7-H1 are disclosed. Additionally, hybridomas or other cell lines expressing such antibodies are disclosed. 133-. (canceled)34. An isolated antibody that specifically binds to B7-H1 having an amino acid sequence comprising:a VH CDR1 having the amino acid sequence of SEQ ID NO: 73; anda VH CDR2 having the amino acid sequence of SEQ ID NO: 74; anda VH CDR3 having the amino acid sequence of SEQ ID NO: 75; anda VL CDR1 having the amino acid sequence of SEQ ID NO: 78; anda VL CDR2 having the amino acid sequence of SEQ ID NO: 79; anda VL CDR3 having the amino acid sequence of SEQ ID NO: 80.35. The antibody of claim 34 , wherein said antibody further comprises an Fc variant claim 34 , wherein the Fc region comprises at least one non naturally occurring amino acid selected from the group consisting of 234F claim 34 , 235F claim 34 , and 331S claim 34 , as numbered by the EU index as set forth in Kabat.36. The antibody of claim 34 , wherein said antibody is monoclonal antibody 2.14H9OPT.37. A purified antibody or antibody fragment claim 34 , wherein the antibody or the fragment immunospecifically binds B7-H1 and comprises a heavy chain variable domain having at least 90% identity to the amino acid of SEQ ID NO:72 and comprises a light chain variable domain having at least 90% identity to the amino acid sequence of SEQ ID NO:77 claim 34 , wherein said antibody has the activity of binding to B7-H1.3837. A nucleic acid molecule encoding the antibody of any one of -.39. A host cell transfected with a vector comprising the nucleic acid molecule of .40. An antibody produced by a method comprising claim 38 , culturing said host cell of claim 38 , expressing an antibody encoded by said nucleic acid molecule of claim 38 , and isolating said antibody from said culture.4137. A composition comprising the ...

Подробнее
Номер записи: 39
04-12-2014 дата публикации

Antigen Binding Proteins that Bind PD-1

Номер: US20140356363A1
Автор: Gray John Dixon, Gros Edwige, Kaufmann Gunnar F., Swanson Barbara A., Zhou Heyue
Принадлежит: Sorrento Therapeutics, Inc.

There is disclosed compositions and methods relating to or derived from anti-PD-1 antibodies. More specifically, there is disclosed fully human antibodies that bind PD-1, PD-1-binding fragments and derivatives of such antibodies, and PD-1-binding polypeptides comprising such fragments. Further still, there is disclosed nucleic acids encoding such antibodies, antibody fragments and derivatives and polypeptides, cells comprising such polynucleotides, methods of making such antibodies, antibody fragments and derivatives and polypeptides, and methods of using such antibodies, antibody fragments and derivatives and polypeptides, including methods of treating or diagnosing subjects having PD-1 related disorders or conditions, including various inflammatory disorders and various cancers. 1. A fully human antibody of an IgG class that binds to a PD-1 epitope with a binding affinity of at least 10M , that has a heavy chain variable domain sequence that is at least 95% identical to the amino acid sequences selected from the group consisting of SEQ ID NO. 1 , SEQ ID NO. 3 , SEQ ID NO. 5 , SEQ ID NO. 7 , SEQ ID NO. 9 , SEQ ID NO. 11 , SEQ ID NO. 13 , SEQ ID NO. 15 , SEQ ID NO. 17 , SEQ ID NO. 19 , SEQ ID NO. 21 , SEQ ID NO. 23 , SEQ ID NO. 25 , SEQ ID NO. 27 , SEQ ID NO. 29 , SEQ ID NO. 31 , SEQ ID NO. 33 , SEQ ID NO. 35 , SEQ ID NO. 37 , SEQ ID NO. 38 , SEQ ID NO. 39 , SEQ ID NO. 40 , SEQ ID NO. 41 , SEQ ID NO. 42 , SEQ ID NO. 43 , SEQ ID NO. 44 , and combinations thereof , and that has a light chain variable domain sequence that is at least 95% identical to the amino acid sequences selected from the group consisting of SEQ ID NO. 2 , SEQ ID NO. 4 , SEQ ID NO. 6 , SEQ ID NO. 8 , SEQ ID NO. 10 , SEQ ID NO. 12 , SEQ ID NO. 14 , SEQ ID NO. 16 , SEQ ID NO. 18 , SEQ ID NO. 20 , SEQ ID NO. 22 , SEQ ID NO. 24 , SEQ ID NO. 26 , SEQ ID NO. 28 , SEQ ID NO. 30 , SEQ ID NO. 32 , SEQ ID NO. 34 , SEQ ID NO. 36 , and combinations thereof.2. The fully human antibody of claim 1 , wherein the ...

Подробнее
Номер записи: 40
04-12-2014 дата публикации

ANTI-SPLA2-V ANTIBODIES AND USES THEREOF

Номер: US20140356379A1
Автор: Lambeau Gérard, Rennou Melanie, Valentin Emmanuel
Принадлежит:

The present disclosure relates to isolated antibodies against human SPLA2-V and uses thereof. 116.-. (canceled)17. An isolated antibody against human sPLA2-V , comprising a variable region of a heavy chain and a variable region of a light chain , wherein the antibody has a Kd for binding to human sPLA2-V less than 1.10M.21. The isolated antibody against human sPLA2-V of claim 20 , wherein the variable region of the light chain comprises at least VL-CDR3: QXXSYPLTF (SEQ ID NO: 7) wherein Xis Y or W and Xis H or S.26. The isolated antibody against human sPLA2-V of claim 17 , wherein the variable region of the heavy chain comprises the following CDRs: SEQ ID NO: 8 (VH-CDR1) claim 17 , SEQ ID NO: 10 (VH-CDR2) and SEQ ID NO: 12 (VH-CDR3) and the variable region of the light chain comprises the following CDRs: SEQ ID NO: 5 (VL-CDR1) claim 17 , SEQ ID NO: 6 (VL-CDR2) and SEQ ID NO: 14 (VL-CDR3).27. The isolated antibody against human sPLA2-V of claim 17 , wherein the variable region of the heavy chain comprises the following CDRs: SEQ ID NO: 9 (VH-CDR1) claim 17 , SEQ ID NO: 11 (VH-CDR2) and SEQ ID NO: 13 (VH-CDR3) and the variable region of the light chain comprises the following CDRs: SEQ ID NO: 5 (VL-CDR1) claim 17 , SEQ ID NO: 6 (VL-CDR2) and SEQ ID NO: 15 (VL-CDR3).28. The isolated antibody against human sPLA2-V of claim 17 , wherein the amino acid sequence encoding the heavy chain variable region is SEQ ID NO: 16 or SEQ ID NO: 18 claim 17 , and the amino acid sequence encoding the light variable region is SEQ ID NO: 17 or SEQ ID NO: 19.29. A method for treating a sPLA2-V-related condition in a subject in need thereof claim 17 , comprising administering a therapeutically effective amount of an antibody of to the subject.30. A method for detecting sPLA2-V in a biological sample claim 17 , comprising the use of an antibody of .31. The method of claim 30 , further defined as a method of performing an in vitro diagnostic or prognostic assay for determining the presence of ...

Подробнее
Номер записи: 41
11-12-2014 дата публикации

METHOD OF TREATING CANCER COMPRISING A VEGF-B ANTAGONIST

Номер: US20140363445A1
Автор: Baca Manuel, Dunlop Felicity Meredith, Fabri Louis Jerry, NASH Andrew, Scotney Pierre David
Принадлежит: ZENYTH OPERATIONS PTY LTD

The present invention relates generally to the field of cancer therapy and prophylaxis. More particularly, the present invention provides growth factor antagonists which inhibit the growth of cancers including tumors and pre-cancerous tissue. Even more particularly, the present invention is directed to antagonists of vascular endothelial growth factor-B and their use to inhibit the growth of cancer including tumor tissue and pre-cancerous tissue. 1. A method of treating cancer in a mammal the method comprising administering to a subject in need thereof an effective amount of a VEGF-B antagonist.2. The method of wherein the cancer is a tumor claim 1 , a pre-cancerous condition claim 1 , a myeloma or a lymphoma.36-. (canceled)7. The method according to wherein the VEGF-B antagonist is an anti-VEGF-B antibody that inhibits binding of VEGF-B to VEGFR-I.814-. (canceled)15. An isolated anti-VEGF-B antibody that inhibits binding of VEGF-B to VEGFR-I wherein the antibody binds human VEGF-B with a Kvalue of 1×10M or less.16. (canceled)17. The antibody of wherein the antibody is human or humanized.1821-. (canceled)22. The antibody of wherein the antibody comprises four claim 15 , five or all six CDR sequences from the heavy and light chain variable regions of mAb 2H10.23. The antibody of wherein the antibody comprises four claim 15 , five or all six CDR sequences from the heavy and light chain variable regions of mAb 2F5.24. The antibody of wherein the antibody comprises four claim 15 , five or all six CDR sequences from the heavy and light chain variable regions of mAb 1C6.25. A composition comprising an antibody of .26. A method of treating cancer in a mammal the method comprising administering to a subject in need thereof an effective amount of an antibody of .27. An isolated anti-VEGF-B antibody according to comprising a light chain with CDRs having the sequences shown in SEQ ID NOs: 5 to 7 claim 17 , or having at least about 80% identity to the sequences shown in SEQ ID ...

Подробнее
Номер записи: 42
08-10-2015 дата публикации

CRYSTAL STRUCTURES OF HETERODIMERIC Fc DOMAINS

Номер: US20150284470A1
Автор: BOULANGER Martin J., DIXIT Surjit Bhimarao, Escobar-Cabrera Eric, LARIO Paula Irene, SPRETER VON KREUDENSTEIN Thomas, SUITS Michael D.L.
Принадлежит:

Disclosed are the atomic coordinates of compositions comprising Fc heterodimer proteins in crystalline form derived from high resolution x-ray diffraction. Further disclosed are systems and methods for using all or a portion of these atomic coordinates to identify and design improved Fc heterodimer proteins. Further disclosed are compositions comprising a mixture of (i) a solubilized Fc heterodimer protein and (ii) a mother liquor solution. The mother liquor solution comprises between 2% and 10% (v/v) ethylene glycol, between 10% and 25% (w/v) polyethylene glycol having an average molecular weight of between 2000 Daltons and 10000 Daltons, and between 0.05 M and 0.40 M ammonium iodide. Further disclosed are systems and methods of identifying a mutation which promotes heterodimeric Fc chain pair formation in which structure based modeling is performed to identify a candidate mutation to an Fc chain using all or a portion of the disclosed three-dimensional atomic coordinates. 1. A composition comprising an Fc heterodimer protein in crystalline form , wherein:said Fc heterodimer protein comprises the amino acid sequences set forth in (i) SEQ ID NOS:2 and 3 or (ii) SEQ ID NOS:4 and 5;{'sub': 1', '1', '1, 'said crystal is in space group P222; and'}said crystal has unit cell dimensions a=49±2 Å, b=75±2 Å, c=149±2 Å, α=β=γ=90°.2. The composition of claim 1 , wherein said Fc heterodimer protein consists of the amino acid sequences set forth in SEQ ID NOS:2 and 3 and has a three dimensional structure characterized by the atomic coordinates of (i) chains A and B of or (ii) chains a and b of .3. The composition of claim 1 , wherein said Fc heterodimer protein consists of the amino acid sequences set forth in SEQ ID NOS:4 and 5 and has a three dimensional structure characterized by the atomic coordinates of (i) chains A and B of or (ii) chains a and b of .4. The composition of claim 1 , wherein said Fc heterodimer protein comprises the amino acid sequences set forth in SEQ ID ...

Подробнее
Номер записи: 43
18-12-2014 дата публикации

NOVEL HETERODIMERIC PROTEINS

Номер: US20140370013A1
Автор: Bernett Matthew J., DESJARLAIS JOHN R., Moore Gregory L., Rashid Rumana
Принадлежит: Xencor, Inc.

The invention provides novel heterodimeric proteins including heterodimeric antibodies. 1. (canceled)2. A composition comprising an anti-CD3 variable region having a sequence comprising a vhCDR1 having the sequence T-Y-A-M-Xaa1 , wherein Xaa1 is N , S or H (SEQ ID NO:435) , a vhCDR2 having the sequence R-I-R-S-K-Xaa1-N-Xaa2-Y-A-T-Xaa3-Y-Y-A-Xaa4-S-V-K-G , wherein Xaa1 is Y or A , Xaa2 is N or S , Xaa3 is Y or A and Xaa4 is D or A (SEQ ID NO:436) , a vhCDR3 having the sequence H-G-N-F-G-Xaa1-S-Y-V-S-W-F-Xaa2-Y , wherein Xaa1 is N , D or Q and Xaa2 is A or D (SEQ ID NO:437) , a vlCDR1 having the sequence Xaa1-S-S-T-G-A-V-T-Xaa2-Xaa3-Xaa4-Y-A-N , wherein Xaa1 is G , R or K , Xaa2 is T or S , Xaa3 is S or G and Xaa4 is N or H , (SEQ ID NO:438) , a vlCDR2 having the sequence Xaa1-T-N-Xaa2-R-A-Xaa3 , wherein Xaa1 is G or D , Xaa2 is K or N , and Xaa3 is P or S (SEQ ID NO:439) and a vlCDR3 having the sequence Xaa1-L-W-Y-S-N-Xaa2-W-V , wherein Xaa1 is A or L and Xaa2 is L or H (SEQ ID NO:440).34-. (canceled)5. A composition according to wherein said composition comprises a first amino acid sequence comprising the variable heavy CDRs and a second amino acid sequence comprising the variable light CDRs.6. A composition according to wherein said composition comprises a scFv.713-. (canceled)14. A nucleic acid composition encoding the composition of .1517-. (canceled)18. A host cell comprising an nucleic acid composition according to .19. A method of making a composition comprising an anti-CD3 variable region comprising culturing a host cell according to under conditions wherein said composition is expressed.20. A method of treating a patient in need thereof by administering a composition according to .21. (canceled)2326-. (canceled)27. A composition according to wherein said composition comprises a scFv.28. (canceled)29. A composition according to wherein said scFv comprises a charged scFv linker.3033-. (canceled)34. A nucleic acid composition encoding a heterodimeric antibody ...

Подробнее
Номер записи: 44
18-12-2014 дата публикации

USES OF MAMMALIAN CYTOKINES AND AGONISTS; RELATED REAGENTS

Номер: US20140370025A1
Автор: Oft Martin
Принадлежит:

Provided are methods of treatment for tumors. In particular, provided are methods of using of a cytokine molecule and its receptor. 1. A method of modulating a neoplasm comprising contacting the neoplasm with an effective amount of TSLP or an agonist thereof.2. The method of claim 1 , wherein the neoplasm is a tumor.3. The method of claim 3 , wherein the tumor is a cancerous tumor.4. The method of claim 3 , wherein the neoplasm is an epithelial derived tumor.5. The method of claim 4 , wherein the epithelial derived tumor is a:a) breast tumor;b) colon tumor;c) lung tumor;d) ovary tumor; ore) prostate tumor.6. The method of claim 1 , wherein the modulating is inhibition of tumor progression.7. The method of claim 6 , wherein the inhibition of tumor progression is tumor rejection.8. The method of claim 7 , wherein the tumor rejection consists of:a) tumor size reduction; orb) loss of metastatic potential.9. The method of claim 1 , wherein the neoplasm contains dendritic cells.10. The method of claim 1 , wherein the agonist is a:a) mutein of TSLP;b) small molecule; orc) agonist antibody.11. A method of treating a subject suffering from a neoplasm comprising administering to the subject an effective amount of TSLP or an agonist thereof.12. The method of claim 11 , wherein the neoplasm is a tumor.13. The method of claim 12 , wherein the tumor is a cancerous tumor.14. The method of claim 13 , wherein the neoplasm is an epithelial derived tumor.15. The method of claim 14 , wherein the epithelial tumor is a:a) breast tumor;b) colon tumor;c) lung tumor;d) ovary tumor; ore) prostate tumor.16. A method of preventing development of a neoplasm comprising a administration to a subject of an effective amount of TSLP or agonist thereof.17. The method of claim 16 , wherein the neoplasm is a tumor.18. The method of claim 17 , wherein the tumor is a cancerous tumor.19. The method of claim 18 , wherein the neoplasm is an epithelial derived tumor.20. The method of claim 19 , wherein the ...

Подробнее
Номер записи: 45
26-11-2015 дата публикации

HUMAN MONOCLONAL ANTIBODIES AGAINST HUMAN CHEMOKINE RECEPTOR CCR6

Номер: US20150337037A1
Автор: Abbasova Svetlana, Ivanova Ekaterina, Kim Eldar, Mikhaylov Roman, Ovchinnikova Elena, Ulitin Andre, Vasilyeva Viktoriia S.
Принадлежит: MSM Protein Technologies

Aspects of this invention include fully human antibodies or fragments thereof that bind specifically to human CCR6 receptor. Such antibodies or fragments thereof can be used to treat disorders involving over function of the CCR6 receptor, including cancers, inflammatory diseases and fibrotic diseases. Other uses include detection of human CCR6 receptor in biological samples for diagnostic or evaluative purposes. 1. A fully human antibody against human chemokine receptor CCR6.24-. (canceled)5. The antibody of claim 1 , further comprising a pharmaceutically acceptable carrier or excipient.6. The antibody of claim 1 , wherein said antibody is essentially free of contaminants.7. The fully human anti-CCR6 antibody of claim 1 , having a CDR3 HC sequence or a CDR3 LC sequence selected from any of Tables 3 through 41.8. The fully human anti-CCR6 antibody of claim 1 , having a CDR3 sequence selected from Tables 3 through 41.9. The antibody of claim 1 , said antibody in IgG1 format.10. The antibody of claim 1 , said antibody in IgG4 format.11. An antibody fragment claim 1 , comprising an scFv or Fab fragment of an antibody of claim 1 , where said antibody fragment specifically binds to human CCR6 with an affinity of between about 1 nM to about 100 nM.12. The antibody of claim 1 , further comprising a physiologically compatible solution.13. The antibody of claim 12 , further comprising one or more physiologically compatible excipients or binders.14. A method for inhibiting an abnormal effect of CCR6 claim 12 , comprising:{'claim-ref': {'@idref': 'CLM-00001', 'claim 1'}, 'administering to a mammal in need thereof an antibody of .'}15. The method of claim 14 , wherein said fully human antibody against CCR6 is an antibody fragment.16. The method of claim 15 , where said antibody fragment is an scFv fragment or a Fab fragment of said antibody having a binding affinity of about 1 nM to about 100 nM.17. (canceled)18. The method of claim 15 , where said antibody or fragment thereof ...

Подробнее
Номер записи: 46
03-12-2015 дата публикации

HETERODIMERIZED POLYPEPTIDE

Номер: US20150344570A1
Автор: Igawa Tomoyuki, Katada Hitoshi, Mimoto Futa, Shiraiwa Hirotake
Принадлежит: Chugai Seiyaku Kabushiki Kaisha

The present inventors produced a heterodimerized polypeptide having an Fc region formed from two polypeptides with different amino acid sequences (a first polypeptide and a second polypeptide), and succeeded in producing a heterodimerized polypeptide containing an Fc region with improved function compared to that of a homodimer in which the Fc region is composed of only the first polypeptide or the second polypeptide by conventional technology. 1. A polypeptide characterized in that the polypeptide is composed of a heterodimer comprising a first polypeptide and a second polypeptide , wherein either one of the first polypeptide and the second polypeptide comprises an Fc region introduced with the mutations of (i) or (ii) , which is a polypeptide whose function of the Fc region is altered compared to a polypeptide comprising an Fc region without mutations:(i) according to EU numbering, the amino acid at position 234 is L, S, F, E, V, D, Q, I, M, T, A, G, or H; the amino acid at position 235 is Y or Q; the amino acid at position 236 is W; the amino acid at position 239 is M or I; the amino acid at position 268 is D; and the amino acid at position 298 is A;(ii) according to EU numbering, the amino acid at position 270 is E; the amino acid at position 326 is D; the amino acid at position 330 is A, K, M, F, I, Y, or H; and the amino acid at position 334 is E.2. The polypeptide of claim 1 , wherein either the first polypeptide or the second polypeptide comprises an Fc region introduced with the mutations of (i) or (ii) claim 1 , and the mutations of (iii) are introduced into the other polypeptide:(i) according to EU numbering, the amino acid at position 234 is L, S, F, E, V, D, Q, I, M, T, A, G or H; the amino acid at position 235 is Y or Q; the amino acid at position 236 is W; the amino acid at position 239 is M or I; the amino acid at position 268 is D; the amino acid at position 298 is A; and the amino acid at position 327 is D;(ii) according to EU numbering, the amino ...

Подробнее
Номер записи: 47
03-12-2015 дата публикации

ANTIBODY TARGETING OSTEOCLAST-RELATED PROTEIN Siglec-15

Номер: US20150344578A1
Автор: Hiruma Yoshiharu, Tsuda Eisuke
Принадлежит: Daiichi Sankyo Company, Limited

To provide a method of detecting abnormal bone metabolism by using a gene strongly expressed in an osteoclast; a method of screening a compound having a therapeutic and/or preventive effect on abnormal bone metabolism; and a pharmaceutical composition for treating and/or preventing abnormal bone metabolism. Provision of a method of detecting abnormal bone metabolism by using the expression of human Siglec-15 gene as an index; a pharmaceutical composition containing an antibody which specifically recognizes human Siglec-15 and has an activity of inhibiting osteoclast formation; and the like. 1. An antibody or an antigen binding fragment thereof , which specifically recognizes any one of the following polypeptides (a)-(i) , or any combination thereof , and inhibits osteoclast formation and/or osteoclastic bone resorption:(a) the amino acid sequence of SEQ ID NO: 2;(b) amino acid residues 21 to 328 of the amino acid sequence of SEQ ID NO: 2;(c) amino acid residues 1 to 260 of the amino acid sequence of SEQ ID NO: 2;(d) amino acid residues 21 to 260 of the amino acid sequence of SEQ ID NO: 2;(e) the amino acid sequence of SEQ ID NO: 4;(f) amino acid residues 21 to 341 of the amino acid sequence of SEQ ID NO: 4;(g) amino acid residues 1 to 258 of the amino acid sequence of SEQ ID NO: 4;(h) amino acid residues 21 to 258 of the amino acid sequence of SEQ ID NO: 4; or(i) an amino acid sequence including substitution, deletion, or addition of one or more a min acid residue in the amino acid sequence described in (a) to (h) wherein the amino acid sequence has a biological activity comparable to that of the amino acid sequence described in (a) to (h).2. The antibody or antigen binding fragment of claim 1 , wherein the antibody is a monoclonal antibody.3. The antibody or antigen binding fragment of claim 1 , wherein the antibody is an IgG antibody.4. The antibody or antigen binding fragment of claim 1 , wherein the antibody or antigen binding fragment competes with an antibody ...

Подробнее
Номер записи: 48
01-03-2016 дата публикации

Inhibitors of receptor tyrosine kinases and methods of use thereof

Номер: US9273134B2
Автор: Irit Lax, Joseph Schlessinger, Satoru Yuzawa, YAN Yang, Yarden Opatowsky
Принадлежит: YALE UNIVERSITY

The present invention provides moieties that bind to an Ig-like domain, e.g., D4 or D5, of a human receptor tyrosine kinase, e.g., the human Kit RTK or the PDGFR RTK, or the D7 domain of a type V receptor tyrosine kinase wherein the moieties lock the ectodomain of the receptor tyrosine kinase in an inactive state thereby antagonizing the activity of the receptor tyrosine kinase.

Подробнее
Номер записи: 49
02-03-2017 дата публикации

항-ｉｌ-１７ａ／ｉｌ-１７ｆ 교차-반응성 항체 및 그의 사용 방법

Номер: KR20170023209A
Автор: 올리비에르 레거, 크르지스즈토프 마스터낙
Принадлежит: 노비뮨 에스 에이

본 발명은 IL-17F, IL-17F 동종이량체, IL-17A, IL-17A 동종이량체, 및/또는 이종이량체성 IL-17A/IL-17F 단백질 복합체를 인식하는 완전 인간 모노클로날 항체를 제공한다. 본 발명은 치료제, 진단제 및 예방제로서 상기 모노클로날 항체를 사용하는 방법을 추가로 제공한다.

Подробнее
Номер записи: 50
31-08-2016 дата публикации

Sclerostin binding agents

Номер: KR101653122B1
Автор: 데이비드 윙클러, 마틴 킴 로빈슨, 시엥 센 루, 아론 조지 윈터스, 알래스테어 로슨, 알리스테어 제임스 헨리, 앤디 포플웰, 웬얀 셴, 존 라쌈, 케빈 그라함, 켈리 수 호프만, 크리스토퍼 파스즈티
Принадлежит: 암젠 인크, 유씨비 파마, 에스.에이.

본 발명은 스클레로스틴 단백질의 에피토프 및 스클레로스틴 결합제, 예를 들면 스클레로스틴과 결합할 수 있는 항체와 관련된 조성물 및 방법을 제공한다. The present invention provides compositions and methods related to an epitope of a sclerostin protein and an antibody capable of binding a sclerostin binding agent, e.g., sclerostin.

Подробнее
Номер записи: 51
24-03-2015 дата публикации

Stabilized liquid anti-RSV antibody formulations

Номер: US8986686B2
Автор: Benjamin S. Isaacs, Christian B. Allan, Cynthia N. Oliver, Erica Shane, Stephen T. Chang
Принадлежит: MEDIMMUNE LLC

The present invention provides liquid formulations of SYNAGIS® or an antigen-binding fragment thereof that immunospecifically bind to a respiratory syncytial virus (RSV) antigen, which formulations exhibit stability, low to undetectable levels of aggregation, and very little to no loss of the biological activities of SYNAGIS® or an antigen-binding fragment thereof, even during long periods of storage. In particular, the present invention provides liquid formulations of SYNAGIS® or an antigen-binding fragment thereof which immunospecifically binds to a RSV antigen, which formulations are substantially free of surfactant, inorganic salts, and/or other common excipients. Furthermore, the invention provides method of preventing, treating or ameliorating symptoms associated with RSV infection utilizing liquid formulations of the present invention.

Подробнее
Номер записи: 52
01-03-2016 дата публикации

Stabilized liquid anti-RSV antibody formulations

Номер: US9272032B2
Автор: Benjamin S. Isaacs, Christian B. Allan, Cynthia N. Oliver, Erica Shane, Stephen T. Chang
Принадлежит: MEDIMMUNE LLC

The present invention provides liquid formulations of SYNAGIS® or an antigen-binding fragment thereof that immunospecifically bind to a respiratory syncytial virus (RSV) antigen, which formulations exhibit stability, low to undetectable levels of aggregation, and very little to no loss of the biological activities of SYNAGIS® or an antigen-binding fragment thereof, even during long periods of storage. In particular, the present invention provides liquid formulations of SYNAGIS® or an antigen-binding fragment thereof which immunospecifically binds to a RSV antigen, which formulations are substantially free of surfactant, inorganic salts, and/or other common excipients. Furthermore, the invention provides method of preventing, treating or ameliorating symptoms associated with RSV infection utilizing liquid formulations of the present invention.

Подробнее
Номер записи: 53
05-05-2015 дата публикации

Anti-cancer agent comprising anti-HB-EGF antibody as active ingredient

Номер: US9023993B2
Автор: Naoki Kimura
Принадлежит: Chugai Pharmaceutical Co Ltd

A monoclonal antibody having a neutralizing activity on HB-EGF is disclosed. The monoclonal antibody of the present invention is preferably an antibody that does not bind to the HB-EGF protein on the cell surface of HB-EGF-expressing cells. Also provided are an anti-cancer agent and a cell proliferation inhibitor, which comprise the monoclonal antibody of the present invention as an active ingredient, and a method of treating cancer, the method comprising administering the monoclonal antibody of the present invention. Cancers that can be treated by the anti-cancer agent of the present invention include pancreatic cancer, liver cancer, esophageal cancer, melanoma, colorectal cancer, gastric cancer, ovarian cancer, bladder cancer, and brain tumors.

Подробнее
Номер записи: 54
20-10-2015 дата публикации

Compositions and methods for binding lysophosphatidic acid

Номер: US9163091B2
Автор: Genevieve Hansen, Gordon Mills, James Stephen Swaney, Jonathan Michael WOJCIAK, Roger A. Sabbadini, Rosalia MATTEO, William A. Garland
Принадлежит: Apollo Endosurgery Inc

Compositions and methods for making and using anti-LPA agents, for example, monoclonal antibodies, are described. Variable domain and complementarity determining region amino acid sequences of several monoclonal antibodies against LPA are disclosed, as is a consensus anti-LPA monoclonal antibody variable domain sequence.

Подробнее
Номер записи: 55
05-01-2016 дата публикации

Anti-cancer drug

Номер: US9226934B2
Автор: Hideaki Tahara, Masahisa Jinushi
Принадлежит: University of Tokyo NUC

The present invention is directed to an anti-cancer drug containing an anti-MFG-E8 antibody as an active ingredient, and to an anti-cancer drug which employs an anti-MFG-E8 antibody in combination with a cancer therapy employing an anti-cancer agent other than the anti-MFG-E8 antibody.

Подробнее
Номер записи: 56
14-07-2015 дата публикации

Diagnosis and treatment of cancer using anti-TMPRSS11E antibody

Номер: US9079957B2
Автор: Hiroyuki Aburatani, Kiyotaka Nakano, Shunpei Ishikawa
Принадлежит: Forerunner Pharma Research Co Ltd, University of Tokyo NUC

[Problem to be Solved] An object of the present invention is to provide novel means for the treatment and diagnosis of cancer. [Solution] The present inventors have obtained a monoclonal antibody against TMPRSS11E and found that this antibody binds to a native form of TMPRSS11E, and TMPRSS11E is highly expressed on the cell membranes of cancer cell lines in flow cytometry. This antibody exhibits antibody-dependent cell-mediated cytotoxicity activity (ADCC activity) and antitumor effect based on internalization activity and is promising as a therapeutic target. Moreover, this antibody has neutralization activity against protease activity and is also expected to have effect brought about by the inhibition of TMPRSS11E functions.

Подробнее
Номер записи: 57
01-11-2016 дата публикации

Antibodies to TGF-β

Номер: US9481726B2
Автор: Alexander R. Duncan, Catriona L. Buchanan, Celia Patricia Hart, Donna K. Finch, Lutz U. Jermutus, Robert G. Holgate, Steven R. Ledbetter
Принадлежит: Genzyme Corp

The present invention relates to antibody molecules, in particular antibody molecules that bind Transforming Growth Factor beta (TGFβ), and uses thereof. More particularly, the invention relates to antibody molecules that bind and preferably neutralize TGFβ1, TGFβ2 and TGFβ3, so-called “pan-specific” antibody molecules, and uses of such antibody molecules. Preferred embodiments within the present invention are antibody molecules, whether whole antibody (e.g. IgG, such as IgG1 or IgG4) or antibody fragments (e.g. scFv, Fab, dAb).

Подробнее
Номер записи: 58
28-07-2015 дата публикации

Antibodies to TGF-beta

Номер: US9090685B2
Автор: Alexander R. Duncan, Catriona L. Buchanan, Celia Patricia Hart, Donna K. Finch, Lutz U. Jermutus, Robert G. Holgate, Steven R. Ledbetter
Принадлежит: Genzyme Corp, Optein Inc

The present invention relates to antibody molecules, in particular antibody molecules that bind Transforming Growth Factor beta (TGFβ), and uses thereof. More particularly, the invention relates to antibody molecules that bind and preferably neutralize TGFβ1, TGFβ2 and TGFβ3, so-called “pan-specific” antibody molecules, and uses of such antibody molecules. Preferred embodiments within the present invention are antibody molecules, whether whole antibody (e.g. IgG, such as IgG1 or IgG4) or antibody fragments (e.g. scFv, Fab, dAb).

Подробнее
Номер записи: 59
18-08-2015 дата публикации

Methods for generating and screening fusion protein libraries and uses thereof

Номер: US9109223B2
Автор: Adrian Schwartz Mittelman, Glen Christopher MacDonald, Jeannick Cizeau, Nicholas Ronald Glover
Принадлежит: Viventia Bio Inc

The invention provides methods for generating fusion protein libraries, such as immunotoxin libraries. The invention also relates to libraries of recombinant cells encoding nucleic acid sequences comprising fusion proteins. In addition, the invention relates to the libraries themselves and the use of the libraries to screen for fusion proteins that are specific for target cells, such as cancer cells. Further, the invention relates to methods of improving fusion proteins and to the improved fusion proteins.

Подробнее
Номер записи: 60
05-01-2016 дата публикации

Compositions and methods for diagnosing and treating cancer

Номер: US9228020B2
Автор: Austin L. Gurney, Fumiko Takada Axelrod, Sanjeev H. Satyal, Timothy Charles Hoey
Принадлежит: OncoMed Pharmaceuticals Inc

An isolated antibody that specifically binds to an extracellular domain of human DLL4 and affects growth of a tumor comprising cancer stem cells is described. Also described is a method of treating cancer comprising administering a therapeutically effective amount of an anti-DLL4 antibody.

Подробнее
Номер записи: 61
06-12-2016 дата публикации

Therapeutic combination and methods of treatment with a DLL4 antagonist and an anti-hypertensive agent

Номер: US9511139B2
Автор: Robert Joseph Stagg, Steven Eugene Benner
Принадлежит: OncoMed Pharmaceuticals Inc

Methods for treating cancer comprising administering a DLL4 antagonist and one or more anti-hypertensive agents are described. Also described are pharmaceutical compositions comprising a DLL4 antagonist and one or more anti-hypertensive agents, and kits comprising the same.

Подробнее
Номер записи: 62
21-02-2017 дата публикации

Stable heterodimeric antibody design with mutations in the Fc domain

Номер: US9574010B2
Автор: David Kai Yuen Poon, Eric Escobar-Cabrera, Paula Irene Lario, Surjit Bhimarao Dixit, Thomas SPRETER VON KREUDENSTEIN
Принадлежит: ZYMEWORKS INC

The provided scaffolds have heavy chains that are asymmetric in the various domains (e.g. CH2 and CH3) to accomplish selectivity between the various Fc receptors involved in modulating effector function, beyond those achievable with a natural homodimeric (symmetric) Fc molecule, and increased stability and purity of the resulting variant Fc heterodimers. These novel molecules comprise complexes of heterogeneous components designed to alter the natural way antibodies behave and that find use in therapeutics.

Подробнее
Номер записи: 63
30-06-2015 дата публикации

Method for making heteromultimeric molecules

Номер: US9067986B2
Автор: Aaron K. Sato, Austin L. Gurney
Принадлежит: OncoMed Pharmaceuticals Inc

Methods for making heteromultimeric molecules, such as bispecific antibodies, and compositions comprising these molecules are disclosed. The methods include introducing mutations in amino acids that are in contact at the interface of two polypeptides, such that the electrostatic interaction between the ion pairs is altered.

Подробнее
Номер записи: 64
28-06-2016 дата публикации

Compositions and methods for diagnosing and treating cancer

Номер: US9376497B2
Автор: Austin Gurney, Fumiko Axelrod, Sanjeev Satyal, Tim Hoey
Принадлежит: OncoMed Pharmaceuticals Inc

An isolated antibody that specifically binds to an extracellular domain of human DLL4 and affects growth of a tumor comprising cancer stem cells is described. Also described is a method of treating cancer comprising administering a therapeutically effective amount of an anti-DLL4 antibody.

Подробнее
Номер записи: 65
15-08-2017 дата публикации

Crystal structures of heterodimeric Fc domains

Номер: US9732155B2
Автор: Eric Escobar-Cabrera, Martin J. Boulanger, Michael D. L. Suits, Paula Irene Lario, Surjit Bhimarao Dixit, Thomas SPRETER VON KREUDENSTEIN
Принадлежит: ZYMEWORKS INC

Disclosed are the atomic coordinates of compositions comprising Fc heterodimer proteins in crystalline form derived from high resolution x-ray diffraction. Further disclosed are systems and methods for using all or a portion of these atomic coordinates to identify and design improved Fc heterodimer proteins. Further disclosed are compositions comprising a mixture of (i) a solubilized Fc heterodimer protein and (ii) a mother liquor solution. The mother liquor solution comprises between 2% and 10% (v/v) ethylene glycol, between 10% and 25% (w/v) polyethylene glycol having an average molecular weight of between 2000 Daltons and 10000 Daltons, and between 0.05 M and 0.40 M ammonium iodide. Further disclosed are systems and methods of identifying a mutation which promotes heterodimeric Fc chain pair formation in which structure based modeling is performed to identify a candidate mutation to an Fc chain using all or a portion of the disclosed three-dimensional atomic coordinates.

Подробнее
Номер записи: 66
24-02-2015 дата публикации

Humanized monoclonal antibodies and methods of use

Номер: US8962806B2
Автор: Jianhua Sui, Quan Zhu, Thomas Küpper, Wayne Marasco
Принадлежит: Bingham and Women's Hospital, Dana Farber Cancer Institute Inc

The present invention comprises a humanized monoclonal antibody that binds to the chemokine receptor CCR4. This antibody is derived from Mab 1567 and recognizes the same epitope. Binding of the invented antibody to CCR4 inhibits ligand-mediated activities and is used to treat symptoms of cancer. Moreover, the antibody is used in combination with vaccines to suppress the activity of regulatory T cells.

Подробнее
Номер записи: 67
03-02-2015 дата публикации

Monovalent, bivalent and trivalent anti human respiratory syncytial virus (HRSV) nanobody constructs for the prevention and/or treatment of respiratory tract infections

Номер: US8945567B2
Автор: Catelijne Stortelers, Erik Depla, Stephanie Staelens
Принадлежит: Ablynx NV

Amino acid sequences are provided that are directed against and/or that can specifically bind protein F of hRSV, as well as to compounds or constructs, and in particular proteins and polypeptides, that comprise or essentially consist of one or more such amino acid sequences. The amino acid sequences, polypeptides and therapeutic compounds and compositions provided by the invention show an improved stability, less immunogenicity and/or improved affinity and/or avidity for protein F of hRSV. The invention also relates to the uses of such amino acid sequences, polypeptides, compounds or constructs for prophylactic and/or therapeutic purposes.

Подробнее
Номер записи: 68
24-02-2015 дата публикации

Single variable domain antibodies against OX40L, constructs and therapeutic use

Номер: US8962807B2
Автор: Frank Verdonck, Sigrid Cornelis, Stephanie Staelens
Принадлежит: Ablynx NV

The present invention relates to immunoglobulin single variable domain sequences that are directed against (as defined herein) OX40L, as well as to compounds or constructs, and in particular proteins and polypeptides, that comprise or essentially consist of one or more such immunoglobulin single variable domain sequences. In particular these immunoglobulin single variable domain sequences can block binding of OX40L to OX40. The immunoglobulin single variable domains, compounds and constructs can be used for prophylactic, therapeutic or diagnostic purposes, such as for the treatment of inflammatory disease and/or disorder such as e.g. asthma, allergic asthma, chronic colitis, Crohn's disease, inflammatory bowel disease, and/or arthrosclerosis.

Подробнее
Номер записи: 69
01-09-2015 дата публикации

Biologic compounds directed against death receptor 5

Номер: US9120855B2
Автор: Bruno DOMBRECHT, David Raymond Stover, Jing Li, Jingxin Zhang, Joost Kolkman, Karen Cromie, Kris MEERSCHAERT, Seth Ettenberg
Принадлежит: NOVARTIS AG

The present invention relates to amino acid sequences that are directed against TRAIL cell surface receptor 2 (herein also “DR5”), as well as to compounds or constructs thereof, and in particular proteins and polypeptides and nucleotides that encode them (referred to herein in their entirety as “NB agents”) and fragments thereof, and pharmaceutically effective variants thereof, and their use in the diagnosis and treatment of DR5 associated diseases and disorders.

Подробнее
Номер записи: 70
22-03-2016 дата публикации

Monoclonal antibody production by EBV transformation of B cells

Номер: US9290786B2
Автор: Antonio Lanzavecchia
Принадлежит: Institute for Research in Biomedicine IRB

A method for producing a clone of an immortalized human B memory lymphocyte, comprising the step of transforming human B memory lymphocytes using Epstein Barr virus (EBV) in the presence of a polyclonal B cell activator. The method is particularly useful in a method for producing a clone of an immortalized human B memory lymphocyte capable of producing a human monoclonal antibody with a desired antigen specificity, comprising the steps of: (i) selecting and isolating a human memory B lymphocyte subpopulation; (ii) transforming the subpopulation with Epstein Ban virus (EBV) in the presence of a polyclonal B cell activator; (iii) screening the culture supernatant for antigen specificity; and (iv) isolating an immortalized human B memory lymphocyte clone capable of producing a human monoclonal antibody having the desired antigen specificity.

Подробнее
Номер записи: 71
24-03-2015 дата публикации

Methods and compositions for treating autoimmune disease

Номер: US8986684B2
Автор: Yi Wang
Принадлежит: Alexion Pharmaceuticals Inc

The disclosure relates to OX-2/CD200 (herein referred to as CD200) antibodies and methods of treating autoimmune disease.

Подробнее
Номер записи: 72
29-12-2015 дата публикации

Combinatorial antibody libraries and uses thereof

Номер: US9221902B2
Автор: Byeong Doo Song, Helen Hongyuan Mao, James Graziano, Omar Bazirgan, Tyson Chase, Vaughn Smider
Принадлежит: FABRUS Inc

Methods for making a combinatorial antibody library from human germline segments are provided. Also provided are libraries of nucleic acid molecules compiled from germline segments encoding VL chains and libraries of nucleic acid molecules encoding VH chains, and resulting antibody libraries. The libraries are provided as addressable libraries. Methods for screening antibody libraries against a target protein antigen, and the identified or selected antibodies are provided.

Подробнее
Номер записи: 73
07-04-2015 дата публикации

Polypeptides and antibodies derived from chronic lymphocytic Leukemia cells and uses thereof

Номер: US8999328B2
Автор: Anke Kretz-Rommel, Katherine S. Bowdish
Принадлежит: Alexion Pharmaceuticals Inc

Small animal models for assessing immunomodulatory effects of compounds are provided.

Подробнее
Номер записи: 74
09-09-2014 дата публикации

Antibodies that block receptor protein tyrosine kinase activation, methods of screening for and uses thereof

Номер: US8828385B2
Автор: Avner Yayon, Elisabeth Thomassen-Wolf, Eran Rom, Eric Borges
Принадлежит: Fibron Ltd

Molecules comprising the antigen-binding portion of antibodies that block constitutive and/or ligand-dependent activation of a receptor protein tyrosine kinase, such as fibroblast growth factor receptor 3 (FGFR3), are found through screening methods, where a soluble dimeric form of a receptor protein tyrosine kinase is used as target for screening a library of antibody fragments displayed on the surface of bacteriophage. The molecules of the present invention which block constitutive activation can be administered to treat or inhibit skeletal dysplasia, craniosynostosis disorders, cell proliferative diseases or disorders, or tumor progression associated with the constitutive activation of a receptor protein tyrosine kinase.

Подробнее
Номер записи: 75
07-04-2015 дата публикации

Antibodies to OX-2/CD200 and uses thereof

Номер: US9000133B2
Автор: Anke Kretz-Rommel, Dayang Wu, Jeremy P. Springhorn, Katherine S. Bowdish, Susan Faas Mcknight
Принадлежит: Alexion Pharmaceuticals Inc

This application provides methods and compositions for modulating and/or depleting CD200 positive cells.

Подробнее
Номер записи: 76
04-11-2014 дата публикации

Polypeptides, antibody variable domains and antagonists

Номер: US8877186B2
Автор: Carolyn Enever, Ian Tomlinson, Laurent Jespers, Malgorzata Pupecka, Michael Steward, Thil Dinuk Batuwangala
Принадлежит: Domantis Ltd

The invention relates to anti-VEGF polypeptides and antibody single variable domains (dAbs) that are resistant to degradation by a protease, as well as antagonists comprising these. The polypeptides, dAbs and antagonists are useful for pulmonary administration, oral administration, delivery to the lung and delivery to the GI tract of a patient, as well as for treating cancer and inflammatory disease, such as arthritis.

Подробнее
Номер записи: 77
01-11-2016 дата публикации

Toll-like receptor 3 antagonists

Номер: US9481731B2
Автор: Alexey Teplyakov, Fang Teng, Jinquan Luo, Katharine Heeringa, Lani San Mateo, Mark Cunningham, Mark Rutz, Raymond Sweet, Robert Rauchenberger, Robert Sarisky, Sheng-Jiun Wu, Vedrana Stojanovic-Susulic, Yiqing Feng
Принадлежит: Janssen Biotech Inc

Toll Like Receptor 3 (TLR3) antibody antagonists, polynucleotides encoding TLR3 antibody antagonists or fragments thereof, and methods of making and using the foregoing are disclosed.

Подробнее
Номер записи: 78
19-01-2016 дата публикации

Method of treating asthma or reducing inflammatory cell lung inflammation by administering toll-like receptor 3 antibodies

Номер: US9238693B2
Автор: Alexey Teplyakov, Fang Teng, Jinquan Luo, Katharine Heeringa, Lani San Mateo, Mark Cunningham, Mark Rutz, Raymond Sweet, Robert Rauchenberger, Robert Sarisky, Sheng-Jiun Wu, Yiqing Feng
Принадлежит: Janssen Biotech Inc

Toll Like Receptor 3 (TLR3) antibody antagonists, polynucleotides encoding TLR3 antibody antagonists or fragments thereof, and methods of making and using the foregoing are disclosed.

Подробнее
Номер записи: 79
20-12-2016 дата публикации

Method of treating an inflammatory condition by administering toll-like 3 receptor antagonists

Номер: US9522957B2
Автор: Alexey Teplyakov, Fang Teng, Jinquan Luo, Katharine Heeringa, Lani San Mateo, Mark Cunningham, Mark Rutz, Raymond Sweet, Robert Rauchenberger, Robert Sarisky, Sheng-Jiun Wu, Yiqing Feng
Принадлежит: Janssen Biotech Inc

Toll Like Receptor 3 (TLR3) antibody antagonists, polynucleotides encoding TLR3 antibody antagonists or fragments thereof, and methods of making and using the foregoing are disclosed.

Подробнее
Номер записи: 80
09-02-2016 дата публикации

Polynucleotides encoding Toll-Like Receptor 3 antagonists

Номер: US9255153B2
Автор: Alexey Teplyakov, Fang Teng, Jinquan Luo, Katharine Heeringa, Lani San Mateo, Mark Cunningham, Mark Rutz, Raymond Sweet, Robert Rauchenberger, Robert Sarisky, Sheng-Jiun Wu, Yiqing Feng
Принадлежит: Janssen Biotech Inc

Toll Like Receptor 3 (TLR3) antibody antagonists, polynucleotides encoding TLR3 antibody antagonists or fragments thereof, and methods of making and using the foregoing are disclosed.

Подробнее
Номер записи: 81
16-05-2017 дата публикации

Heterodimeric proteins

Номер: US9650446B2
Автор: Gregory Moore, John Desjarlais, Matthew Bernett, Rumana Rashid
Принадлежит: Xencor Inc

The invention provides novel heterodimeric proteins including heterodimeric antibodies.

Подробнее
Номер записи: 82
22-08-2017 дата публикации

Rapid clearance of antigen complexes using novel antibodies

Номер: US9738722B2
Автор: Gregory L. Moore, John Desjarlais, Matthew Bernett
Принадлежит: Xencor Inc

The present invention relates to rapid clearance molecules that bind target antigens and FcγRIIb with increased affinity as compared to parent molecules, the compositions being capable of causing accelerated clearance of such antigens. Such compositions are useful for treating a variety of disorders, including allergic diseases, atherosclerosis, and a variety of other conditions.

Подробнее
Номер записи: 83
23-05-2017 дата публикации

Optimized Fc variants

Номер: US9657106B2
Автор: Gregory Lazar, John Desjarlais, Jost Vielmetter, Omid Vafa, Robert Hayes, Sher Karki, Wei Dang
Принадлежит: Xencor Inc

The present invention relates to Fc variants having decreased affinity for FcγRIIb, methods for their generation, Fc polypeptides comprising optimized Fc variants, and methods for using optimized Fc variants.

Подробнее
Номер записи: 84
30-05-2017 дата публикации

Optimized Fc variants

Номер: US9663582B2
Автор: Gregory Lazar, John Desjarlais, Jost Vielmetter, Omid Vafa, Robert Hayes, Sher Karki, Wei Dang
Принадлежит: Xencor Inc

The present invention relates to Fc variants having decreased affinity for FcγRIIb, methods for their generation, Fc polypeptides comprising optimized Fc variants, and methods for using optimized Fc variants.

Подробнее
Номер записи: 85
22-11-2016 дата публикации

Anti-FGFR3 antibodies and methods using same

Номер: US9499623B2
Автор: Avi Ashkenazi, Christian Wiesmann, Jing Qing, Yan Wu
Принадлежит: Genentech Inc

The invention provides FGFR3 antibodies, and compositions comprising and methods of using these antibodies.

Подробнее
Номер записи: 86
20-10-2015 дата публикации

Anti-FGFR3 antibodies and methods using same

Номер: US9161977B2
Автор: Avi Ashkenazi, Christian Wiesmann, Jing Qing, Yan Wu
Принадлежит: F Hoffmann La Roche AG

The invention provides FGFR3 antibodies, and compositions comprising and methods of using these antibodies.

Подробнее
Номер записи: 87
23-02-2016 дата публикации

Anti-Bv8 antibodies and uses thereof

Номер: US9266948B2
Автор: Janet Tien, Lanlan Yu, Napoleone Ferrara, Van Wu, Wei-Ghing Liang, Xiumin Wu, Yu-Ju G. Meng
Принадлежит: Genentech Inc

The present invention concerns antibodies to Bv8 and the uses of same.

Подробнее
Номер записи: 88
16-09-2014 дата публикации

Humanized anti-beta7 antagonists and uses therefor

Номер: US8835133B2
Автор: Mark S. Dennis, Sherman Fong
Принадлежит: Genentech Inc

The invention provides therapeutic anti-beta7 antibodies, compositions comprising, and methods of using these antibodies.

Подробнее
Номер записи: 89
28-04-2015 дата публикации

Immunomodulating tumor necrosis factor receptor 25 (TNFR25) agonists, antagonists, and immunotoxins

Номер: US9017679B2
Автор: Eckhard R. Podack, Robert Levy, Vadim Deyev
Принадлежит: UNIVERSITY OF MIAMI

Compositions and methods utilizing immunomodulating agents can either stimulate or indirectly augment the immune system or have an immunosuppressive effect. TNFR25 agonists disclosed herein have an anti-inflammatory and healing effect. They can be used to treat disease caused by asthma and chronic inflammation such as inflammatory bowel diseases including ulcerative colitis and Crohn's Disease. TNFR25 antagonists disclosed herein are capable of inhibiting CD8 T cell-mediated cellular immune responses and can for example, mitigate organ or tissue rejection following a tissue transplantation.

Подробнее
Номер записи: 90
22-11-2016 дата публикации

Method for in vivo expansion of T regulatory cells

Номер: US9499627B2
Автор: Dietlinde-Maria Wolf, Eckhard R. Podack, Taylor Schreiber
Принадлежит: UNIVERSITY OF MIAMI

Compositions specific for TNF-receptor superfamily member 25 (TNFRSF25, DR3) modulate the immune response by regulating T regulatory cells.

Подробнее
Номер записи: 91
24-03-2015 дата публикации

Trans-capsular administration of p38 map kinase inhibitors into orthopedic joints

Номер: US8986696B2
Автор: Carrie H. Fang, Jeffery C. Geesin, John J. Siekierka, Laura J. Brown
Принадлежит: DePuy Mitek LLC

The present invention relates to trans-capsularly administering into a diseased joint an inhibitor of p38 MAP kinase or a different therapeutic agent.

Подробнее
Номер записи: 92
09-12-2014 дата публикации

Human anti-IFN-γ neutralizing antibodies as selective IFN-γ pathway inhibitors

Номер: US8906371B2
Автор: Andrew A. Welcher, Haichun Huang, Hilary T. Chute, Yue-Sheng Li
Принадлежит: AMGEN INC, ER Squibb and Sons LLC

This invention provides antibodies that interact with or bind to human interferon-gamma (IFN-γ) and methods for treating IFN-γ mediated diseases by administering a pharmaceutically effective amount of antibodies to IFN-γ. Methods of detecting the amount of IFN-γ in a sample using antibodies to IFN-γ are also provided.

Подробнее
Номер записи: 93
03-05-2016 дата публикации

Human antibodies that bind human MAdCAM

Номер: US9328169B2
Автор: Elizabeth Molloy, Larry L. Green, Mary Haak-Frendscho, Nicholas Pullen, Sirid-Aimee Kellermann
Принадлежит: Amgen Fremont Inc, PFIZER INC

The present invention relates to antibodies, including human antibodies, and antigen-binding portions thereof that specifically bind to MAdCAM, preferably human MAdCAM, and inhibit MAdCAM. The antibodies comprise the CDRs or variable domains derived from an antibody produced by the hybridoma cell line 7.16.6 (ECACC Accession No. 03090909) or from an antibody comprising the amino acid sequences of SEQ ID NOs.: 34 and 36. The invention also relates to nucleic acid molecules encoding such antibodies and antigen-binding portions thereof, methods of making and using the antibodies and portions, and compositions comprising these antibodies and portions.

Подробнее
Номер записи: 94
19-01-2016 дата публикации

Antibodies to MAdCAM

Номер: USRE45847E1
Автор: Elizabeth Molloy, Larry L. Green, Mary Haak-Frendscho, Nicholas Pullen, Sirid-Aimee Kellermann
Принадлежит: Amgen Fremont Inc, PFIZER INC

The present invention relates to antibodies including human antibodies and antigen-binding portions thereof that specifically bind to MAdCAM, preferably human MAdCAM and that function to inhibit MAdCAM. The invention also relates to human anti-MAdCAM antibodies and antigen-binding portions thereof. The invention also relates to antibodies that are chimeric, bispecific, derivatized, single chain antibodies or portions of fusion proteins. The invention also relates to isolated heavy and light chain immunoglobulins derived from human anti-MAdCAM antibodies and nucleic acid molecules encoding such immunoglobulins. The present invention also relates to methods of making human anti-MAdCAM antibodies, compositions comprising these antibodies and methods of using the antibodies and compositions for diagnosis and treatment. The invention also provides gene therapy methods using nucleic acid molecules encoding the heavy and/or light immunoglobulin molecules that comprise the human anti-MAdCAM antibodies. The invention also relates to transgenic animals or plants comprising nucleic acid molecules of the invention.

Подробнее
Номер записи: 95
25-11-2014 дата публикации

Antibodies directed to αVβ6 and uses thereof

Номер: US8894998B2
Автор: Avril Alfred, Ian Foltz, Julie Rinkenberger, Simon Thomas Barry, Vahe Bedian
Принадлежит: MedImmune Ltd

Targeted binding agents, such antibodies directed to the antigen αVβ6 and uses of such agents are described. In particular, fully human monoclonal antibodies directed to the antigen αVβ6 are disclosed. Nucleotide sequences encoding, and amino acid sequences comprising, heavy and light chain immunoglobulin molecules, particularly sequences corresponding to contiguous heavy and light chain sequences spanning the framework regions and/or complementarity determining regions (CDR's), specifically from FR1 through FR4 or CDR1 through CDR3 are disclosed. Hybridomas or other cell lines expressing such immunoglobulin molecules and monoclonal antibodies are also disclosed.

Подробнее
Номер записи: 96
21-07-2015 дата публикации

Antibodies to IL-6 to inhibit or treat inflammation

Номер: US9085615B2
Автор: Ann Elisabeth CARVALHO JENSEN, Benjamin H. Dutzar, Brian R. Kovacevich, Ethan W. Ojala, Jeffrey T. L. Smith, John A. Latham, Katie Anderson, Leon F. Garcia-Martinez
Принадлежит: ALDERBIO HOLDINGS LLC

The present invention is directed to therapeutic methods using IL-6 antagonists such as an Ab1 antibody or antibody fragment having binding specificity for IL-6 to prevent or treat disease or to improve survivability or quality of life of a patient in need thereof. In preferred embodiments these patients will comprise those exhibiting (or at risk of developing) an elevated serum C-reactive protein level, reduced serum albumin level, elevated D-dimer or other coagulation cascade related protein(s), cachexia, fever, weakness and/or fatigue prior to treatment. The subject therapies also may include the administration of other actives such as chemotherapeutics, anti-coagulants, statins, and others.

Подробнее
Номер записи: 97
26-01-2016 дата публикации

Antagonists of IL-6 to raise albumin and/or lower CRIP

Номер: US9241990B2
Автор: Jeffrey T. L. Smith
Принадлежит: ALDERBIO HOLDINGS LLC

The present invention is directed to therapeutic methods using IL-6 antagonists such as antibodies and fragments thereof having binding specificity for IL-6 to improve survivability or quality of life of a patient in need thereof. In preferred embodiments these patients will comprise those exhibiting (or at risk of developing) an elevated serum C-reactive protein level or a reduced serum albumin level prior to treatment. In another preferred embodiment, the patient's Glasgow Prognostic Score will be increased and survivability will preferably be improved.

Подробнее
Номер записи: 98
11-07-2017 дата публикации

Method of improving patient survivability and quality of life by anti-IL-6 antibody administration

Номер: US9701747B2
Автор: Jeffrey T. L. Smith
Принадлежит: ALDERBIO HOLDINGS LLC

The present invention is directed to therapeutic methods using IL-6 antagonists such as antibodies and fragments thereof having binding specificity for IL-6 to improve survivability or quality of life of a patient in need thereof. In preferred embodiments these patients will comprise those exhibiting (or at risk of developing) an elevated serum C-reactive protein level or a reduced serum albumin level prior to treatment. In another preferred embodiment, the patient's Glasgow Prognostic Score will be increased and survivability will preferably be improved.

Подробнее
Номер записи: 99
08-08-2017 дата публикации

Expression vectors containing isolated nucleic acids encoding anti-human IL-6 antibody

Номер: US9725509B2
Автор: Anne Elisabeth Carvalho Jensen, Benjamin H. Dutzar, Brian R. Kovacevich, Ethan W. Ojala, Jeffrey T. L. Smith, John Latham, Katie Anderson, Leon Garcia-Martinez
Принадлежит: ALDERBIO HOLDINGS LLC

The invention relates to anti-human interleukin 6 antibodies and antibody fragments, nucleic acids and vectors which encode for these antibodies and antibody fragments the use thereof in therapy and diagnosis.

Подробнее
Номер записи: 100